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Abstract 
 
Meningiomas are the commonest primary intracranial tumours. With the increased 
access to neuro-radiological investigations, there has been a tremendous increase in 
the number of incidental findings. Incidental meningioma accounts for 10% of these 
findings and for 30% of newly-diagnosed meningiomas. International guidelines 
advise that these tumours are best managed using active clinical-radiological 
monitoring, however, duration of surveillance and intervals in between scans, remain 
unspecified. This uncertainty has economic implications and causes patient anxiety. 
Previous literature has focused primarily on radiological prognostication with little 
attention to the effect of clinical factors such as comorbidity and performance status 
on prognosis of incidental meningiomas. Moreover, the temporal relationship 
between these factors and progression remains poorly defined. 
The aims of this thesis therefore were to investigate the prognostic relationship 
between radiological factors and the timing of progression and to examine how this 
is augmented by clinical factors including patient age, comorbidity and performance 
status. Moreover, a predictive model of progression was built based on these factors 
and used to inform duration of follow-up and appropriate time-points for scans. 
Radiological factors included in the model were: increasing tumour volume, 
peritumoural signal change, MR FLAIR/T2 hyperintense meningiomas and proximity 
to critical neurovascular structures. Patients were stratified into low, medium and 
high-risk groups and rates of disease progression at 5-years were 3%, 28% and 75% 
respectively. Low-risk patients had non-oedematous, small iso/hypointense 
meningiomas, distant from neurovascular structures. Older patients with co-
morbidities were 15-times more likely to die than to receive intervention at 5-years 
following diagnosis, regardless of risk-group. After 5-years of follow-up the 
probability of disease progression plateaued in all risk groups. Active monitoring 
strategies based on these results were formulated. These have the potential to 
reduce the cost burden of incidental meningiomas. Prospective studies are needed 
to validate the model.  
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Chapter 1: An Introduction to Meningiomas 
Meningioma, a term first used by Cushing in 1922, is an extra-axial tumour that arises from 
the arachnoid cap cells (1). It represents more than a third of intracranial and intraspinal 
primary tumours and can manifest in a variety of symptoms depending on its location. With 
the extensive application of neuro-imaging modalities for purposes such as diagnostics and 
research, more of these tumours are being discovered whilst in a clinically dormant state. 
These are referred to as incidental meningiomas.  
1.1. Epidemiology and natural history  
Meningiomas have the highest incidence rate amongst all primary central nervous system 
(CNS) tumours. Descriptive studies from Europe and North America suggest this rate to be 
between 4.20 and 7.86 per 100,000 individuals. Their incidence increases with age and peaks 
between the 5th and 7th decades of life. The female to male ratio is approximately 2:1 (2-4). 
These descriptive studies do not make the distinction between cerebral and spinal tumours. 
They are additionally limited by inclusion of only histologically-verified meningiomas. This 
means that the aforementioned rates might be underestimated as they do not account for 
radiologically-diagnosed meningiomas that remain asymptomatic until death. This is evident 
in autopsy studies which report an undiagnosed meningioma prevalence of 0.3-2.3% (5-7).  
The natural history of untreated meningiomas has been well described in the literature; most 
exhibit indolent growth rates and some, followed for a number of years, prove to be static 
(8, 9). In addition, several factors that contribute to increased growth rates have been 
identified. These include absence of calcification within the tumour, increased signal 
intensity on T2-weighted (T2) magnetic resonance imaging (MRI) and tumour size (10). 
Multiplicity does not seem to have an impact on growth potential (11).  
1.2. Location and clinical presentation  
The majority of meningiomas are found supratentorially, most commonly along the dural 
venous sinuses in the cerebral convexity, and along the falx cerebri. These localisations 
account for approximately 60% of cerebral meningiomas. Less common sites include the 
ventricles. They could also be found in the skull base alongside structures such as the 
olfactory groove, sphenoid wing and the clivus. The distribution of locations can be found in 
Table 1.1 (12, 13). These meningiomas, if sizeable or oedematous, can present with 
headaches, seizures or focal neurological deficits such as unilateral weakness, speech 
disturbance and personality changes (14, 15).  
Table 1.1. The distribution of intracranial meningioma location 
Location  Percentage (%) 
Cerebral convexity  20-34 
Parasagittal and parafalcine  18-22 
Sphenoid and middle cranial fossa  17-25 
Anterior midline  10 
Posterior fossa  9-15 
Intraventricular  2-5  
Orbital  1-2  
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Thoracic meningiomas constitute roughly 60% of intradural extramedullary spinal 
meningiomas. Symptoms on presentation include motor and sensory deficits, sphincter 
dysfunction and gait ataxia. Lumbar meningioma is uncommon (16, 17).  
An increasing number of meningiomas is still asymptomatic when discovered, particularly 
those within the cranium (18). These will be the main topic of discussion in this thesis.  
1.3. Grading and histology  
The World Health Organisation (WHO) classifies meningiomas into three groups (19):  
• Benign meningioma (grade I). 
• Atypical meningioma (grade II). 
• Anaplastic meningioma (grade III). 
The latest 2016 classification reported the addition of brain invasion as a sole criterion for 
diagnosis of atypical meningioma. This in addition to other histological diagnostic parameters 
can be found in Table 1.2.  
Table 1.2. The WHO classification of meningiomas  
Grades I II III 
Diagnostic 
parameters 
4 mitoses/10 hpf 4–19 mitoses/10 hpf 
OR 
3 of the following 5: 
sheet-like growth, 
spontaneous necrosis, 
high nuclear to 
cytoplasmic ratio, 
prominent nucleoli, and 
increased cellularity 
OR 
brain Invasion 
≥20 mitoses/10 hpf 
OR 
frank anaplasia 
OR 
rhabdoid/papillary 
histology 
Histological 
subtypes 
meningothelial, 
fibroblastic, transitional, 
psammomatous, 
angiomatous, 
microcystic, secretory, 
lymphoplasmacyte-rich, 
and metaplastic 
Atypical, clear cell and 
chordoid 
Anaplastic, rhabdoid 
and papillary 
Frequency (%) 80-90 5-10 1-5 
Abbreviations: hpf= high-power field 
 
This change is likely to increase the proportion of atypical meningiomas. It will also have an 
impact on clinical outcomes; however, comparative reports are still in process.  
1.4. Aetiology  
Although most meningiomas are hypothesised to occur sporadically, cytogenetic and 
molecular studies imply that chromosome 22 aberrations are involved in up to 70% of 
tumours (20, 21). This is in keeping with the association between neurofibromatosis-2 (NF2) 
and the increased incidence of meningiomas. NF2, a rare genetic syndrome, predisposes its 
carriers to benign intracranial tumours. The cardinal feature is the development of bilateral 
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vestibular schwannomas. Meningioma is the second most frequent tumour type affecting up 
to half of patients. The tumour suppressor NF2 gene is located on the long arm of 
Chromosome 22 (22q12.2); 50% of mutations are familial inherited in an autosomal 
dominant manner whilst the rest are sporadic (22-24). Other genes such as SOD, DAL1, AKT1, 
SMO and TRAF7 are implicated but to a lesser extent (25, 26). Whilst these mutations, 
particularly of the NF2 gene, are consistently observed in benign grade I meningiomas, high 
grade tumours exhibit a different variety of genetic karyotypes. This suggests that beyond 
meningioma development, NF2 might have a limited role in malignant progression (27).  
Meningiomas have also been observed to occur as a result of ionizing radiation (28). This 
observation is supported by large-scale studies done on 11,000 Israeli adults irradiated for 
tinea capitis during childhood, and Hiroshima and Nagasaki survivors (29-32). Based on 
radiation dose, these meningiomas can be split into 3 categories: low-dose (<10 Grey (Gy)), 
medium-dose (10-20 Gy) and high-dose (>20 Gy) (33). High-dose meningiomas demonstrate 
a shorter latency period as opposed to low-dose meningiomas. Clinical and histopathological 
aggressiveness also correlates with the amount of radiation administered (28).    
Researchers have additionally investigated the relationship between endogenous or 
exogenous hormone exposure and meningiomas. This is due to the following observations:  
• A female preponderance particularly amongst those of reproductive age.   
• Expression of hormone receptors in meningioma cell lines. 
• A link with breast cancer. 
• Changes in the size of meningiomas during periods of hormone fluctuations such as 
pregnancy and menopause. 
These investigations have been inconclusive (34-36).  
1.5. Pathogenesis  
Neoplastic meningioma cells like their normal counterparts exhibit some degree of overlap 
with mesenchymal and epithelial cells. Encapsulating the brain and the spine are three 
meningeal layers: the dura mater, arachnoid mater and pia mater. Histologically, the 
arachnoid mater is composed of arachnoid cap cells which cytologically resemble 
meningioma tumour cells. Therefore, it is widely accepted that these cap cells represent the 
most likely site of origin (37, 38). The process of tumorigenesis is highly linked to a protein 
named Moesin-Ezrin-Radixin-Like Protein. This is often referred to as Merlin. This protein, 
which is encoded by the frequently mutated NF2 gene in meningiomas, has been 
demonstrated to regulate several processes; these include cell migration and proliferation 
(39). It has also been shown to be implicated in regulating the mammalian target of 
rapamycin complex 1 (mTORC1) which is dysfunctional in several human cancers (40, 41). 
The process of malignant transformation, likely to be independent of NF2 as previously 
discussed, is linked to several candidate chromosomes. These include: 1, 9, 10 and 14, 
amongst several others (42, 43).  
Meningiomas are highly variable in regard to vascularity and peritumoural oedema, which 
have been shown to influence prognosis (44). Vascular endothelial growth factor A (VEGF-A) 
has been suggested to regulate both processes via pathological angiogenesis of cerebral-pia 
4 
 
blood vessels (45). Bone invasion or hyperostosis is also characteristic of many meningiomas, 
particularly those found along skull base structures (46). Potential candidate regulating 
proteins include osteoblast stimulating factors such as alkaline phosphatase (47, 48). Brain 
invasion, which reflects a more aggressive nature amongst meningiomas, is driven by extra-
cellular matrix (ECM) proteins such as matrix metalloproteinase-9 (MMP-9) (49, 50). This is 
similar to other aggressive malignancies (50).   
These genetic alterations increase the susceptibility of individuals to develop meningiomas 
(51); therefore, molecular and genetic characterisation is vital as to enable the use of 
personalised medicine in managing these patients (52).   
1.6. Diagnosis  
The majority of meningiomas can be confidently diagnosed using the combination of MRI 
and computed tomography (CT) (53). MRI sequences performed for this purpose include T1-
weighted (T1), T2 and fluid-attenuated inversion recovery (FLAIR). Meningiomas are typically 
isointense on T1 and iso/hyperintense on the latter. The addition of a contrast agent such as 
gadolinium to T1 leads to a vivid enhancing appearance; it also frequently demonstrates the 
typical “dural tail” feature, which is thickening of the dura mater adjacent to the tumour. T2 
and FLAIR are useful for detecting peritumoural oedema (54). CT is an important adjunct as 
to further characterise tumour calcification and hyperostosis (55).  
Although once the modality of choice for diagnosis (56), cerebral angiography has now 
become outdated; however, it is important that MRI venography is performed as to establish 
venous patency for meningiomas in proximity of major dural sinuses and veins (57).  
Nuclear imaging modalities such as positron emission tomography (PET) and single photon 
emission computed tomography (SPECT) could also be used for the purpose of diagnosis (58). 
Several radiotracers could be employed; these include 1-11C-Acetate and gallium-68 DOTA-
DPhe1, Tyr3-octreotate (68Ga-DOTATATE). The majority of meningiomas have been shown to 
express somatostatin receptor subtype 2 (SSTR2) which is highly affinitive for 68Ga-
DOTATATE; therefore, its diagnostic use in delineating meningioma cells from tumour-free 
tissue is promising (59). 
The utility of those previous imaging modalities has also been investigated for predicting 
meningioma grade and recurrence rates; however, histopathological diagnosis, as outlined 
by the WHO classification, remains the gold standard (60). 
1.7. Prognosis 
Although most meningiomas are benign in nature, overall survival does seem to be shorter 
in those affected. Historic population-based studies from Europe demonstrated 10-year 
relative survival rates between 86% and 92% when compared to matched populations (61, 
62). These studies however are outdated. 
Studies have also addressed the influence of patient and clinical characteristics, imaging 
findings and choice of intervention on prognosis. Several factors are implicated including 
tumour grade, surgical resection and patient age (60, 63, 64). The attention has however now 
shifted towards studying the impact of molecular and genetic alterations in meningiomas 
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which most likely will uncover more aspects to prognosis and subsequently management 
(65).  
Moreover, due to increasingly effective treatment approaches over the past decades, we are 
now observing prolonged treatment journeys for meningioma patients. As a result, studies 
have attempted to assess their effect on quality of life (QoL) and neurocognition function 
(NCF). Two recent systematic reviews concluded that meningioma patients suffer with 
dysfunction in several cognitive domains, and that meningioma patients fare worse in 
regards to QoL than healthy controls (66, 67); this merits further studies assessing the impact 
of previously investigated factors on QoL and NCF alongside conventional clinical measures 
such as progression and survival.  
1.8. Management strategies  
Meningiomas are heterogeneous tumours ranging in spectrum from small, slow-growing 
lesions, to large progressive masses, invading brain parenchyma and engulfing cranial nerves. 
Therefore, treatment should be personalised with patient, clinical and radiological factors 
being considered.  
Management options include surgery, radiotherapy and active monitoring. Surgical trials 
pose many methodological challenges and thus up to this date, there have been no 
randomised controlled trials comparing these modalities (68); hence, the majority of 
recommendations are based on retrospective and prospective observational studies.  
1.8.1. Symptomatic meningiomas  
1.8.1.1. Surgery  
Ever since the inception of Simpson’s score for resection, meningioma surgery has been the 
mainstay treatment for most symptomatic tumours (69). Over the past thirty years or so, 
intraoperative navigation, microscopic surgery and minimally invasive endoscopes have 
revolutionised the world of neurosurgery and have helped introduce a vast number of novel 
surgical techniques. Meningioma surgery, however, is still primarily underpinned by key 
principles which are early tumour devascularisation and internal debulking followed by 
peripheral dissection (70). The main objectives are to achieve safe maximal resection, 
without inflicting any significant neurological deficits, relieve mass effect and subsequently 
alleviate symptoms; there’s also the added benefit of diagnostic verification and 
histopathological characterisation (69). 
 
Preoperatively, patients with significant peritumoural oedema and associated neurological 
deficits should be offered steroids (71). Certain meningiomas could also be subjected to 
embolisation, where certain materials such as polyvinyl alcohol (PVA) particles and porous 
cellulose beads, delivered via microcatheters, are used to obliterate the corresponding blood 
supply (72). The potential advantages include reduced intraoperative blood loss, and 
softening of the tumour, all of which could facilitate a technically less difficult surgery and 
increase the likelihood of achieving a more complete resection (73). Embolization, however, 
carries risks including infarction and cranial nerve palsies with an incidence rate ranging from 
as high as 12.6% to approximately 3.0% (74). Moreover, evidence does not suggest better 
outcomes in comparison to non-embolised meningiomas and there’s no consensus regarding 
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the specific indications (75). As a result, whether to embolise or not, remains a matter of 
personal preference and prospective controlled trials are needed to better define indications 
and outcomes.  Neurosurgeons frequently also prescribe prophylactic antiepileptic drugs in 
aim of reducing the rate of postoperative seizures following excision of intracranial 
meningiomas (76), however, recent systematic reviews demonstrated that these should not 
be given routinely and that again randomised trials are needed to shape clinical practice (77).    
 
Recurrence rates following extirpation of grade I tumours depend mainly on extent of 
resection (EOR). This is usually defined using Simpson’s grading (78); Table 1.3, which despite 
being previously challenged for its use as a prognostic factor (79, 80), still maintains its 
relevance as shown by more recent series (81, 82).  
 
A previous investigation observed no significant difference in recurrence rates amongst 
grades 1, 2 and 3 of resection and another extended this observation to include grade 4. 
More recent studies however have challenged this notion; Table 1.4. These observational 
variations might stem from methodological differences, and distinct follow-up times and 
sample sizes; whist those in favour of Simpson’s criteria uniformly classified all cases 
according to the 2007 WHO grading system (82), other authors did not specify whether this 
was carried out for meningiomas diagnosed prior to 2007 (79, 80). 
 
Additionally, the follow-up times were relatively shorter than the average time of 62 months 
between surgery and confirmation of recurrence in Simpson’s report. This disparity might 
have also been due to the subjective variability amongst surgeons in intraoperative 
assessment of resection, and as such the European Association of Neuro-Oncology (EANO) 
advocates confirmation of this by postoperative MRI (69). Regardless, in recognition of this 
issue, EOR could be classified into gross total resection (GTR) or subtotal resection (STR). GTR 
is described as Simpson I-III, while STR corresponds to Simpson IV-V. These definitions have 
been endorsed by both the European Organisation for Research and Treatment of Cancer 
(EORTC) and the Radiation Therapy Oncology Group (RTOG) (83).  
 
Furthermore, tumour location was previously thought to have an impact on prognosis (84, 
85); more recent series however, have nullified this demonstrating the effect of new surgical 
technologies and techniques on EOR and consequently recurrence rates (81, 82). 
Table 1.3. Simpson’s grades of meningioma resection  
Grade Description  
1 Macroscopically complete removal of tumour, with excision of 
its dural attachment, and of any abnormal bone. Includes 
resection of venous sinus if involved 
Gross total resection 
(GTR) 
2 Macroscopically complete removal of tumour and its visible 
extensions with coagulation of its dural attachment 
3 Macroscopically complete removal of the intradural tumour, 
without resection or coagulation of its dural attachment or its 
extradural extensions 
4 Partial removal, leaving intradural tumour in situ Subtotal resection 
(STR) 5 Simple decompression, with or without biopsy 
  
7 
 
 
There has also been a shift now in the management of cranial base and venous sinus 
meningiomas moving away from radical resection and towards conservative surgery, where 
residual tumour could be left to avoid devastating neurological deficits. This residual could 
be monitored postoperatively with serial MRI or may be treated with adjuvant radiotherapy 
(87). This will be elaborated upon in the next section.  
WHO grade II and III meningiomas are more aggressive and they exhibit a significant 
predisposition to recur following surgery. Indeed, the 5-year recurrence rates are quoted at 
approximately 40% and 55% respectively (88-93). These rates again, similarly to grade I 
tumours, largely depend on EOR. Other factors’ prognostic effect including age, gender, Ki-
67 status and tumour size is debatable with studies demonstrating conflicting results (90, 94-
96). Lastly, whilst adjuvant radiotherapy has been shown to influence progression and 
recurrence following resection of anaplastic meningiomas, its role is yet to be defined for 
atypical meningioma (97).  
Since EOR has been consistently observed to impact recurrence rates, intraoperative 
technologies such as fluorescence guided surgery and intra-operative MRI (iMRI) have been 
developed to aid this. A recent Cochrane review however showed that current evidence is of 
a low quality and that the application of these technologies in routine meningioma practice 
is yet to be established (98).  
1.8.1.2. Radiotherapy  
The anti-tumour activity of radiation is due to double-strand-DNA damaging free radicals 
which lead to multiple consequences including cell death (99). The application of this in 
meningioma practice has evolved greatly over the past decades; from being historically 
considered a radioresistant entity to its resurgence becoming the topic of multiple 
investigations, now available to us are several ways of delivery, these include: external beam 
radiation therapy (RT) and radiosurgery (RS) (100, 101).  
1.8.1.2.1. RT 
RT primarily relies on the radiobiologic linear-quadratic (LQ) model. In this model, the 
response of normal or tumour tissue to radiation is dictated by a single clinical parameter: 
the α/β ratio; α refers to the cell’s “intrinsic radiosensitivity” whilst β reflects its “repair 
Table 1.4. Meningioma recurrence rates (%) associated with Simpson’s 5 grades of resection in 5 
selected studies 
Authors and year 
N. of 
patients 
Follow-up time 1 2 3 4 5 
Simpson, 1957 (78) 265 62 months* 9 19 29 44 100 
Sughrue et al., 2012 (86) 373 44.4 months† 5 15 13 19 - 
Oya et al., 2012 (80) 240 - 2.4 12.3 15.9 53.2 - 
Gallagher et al., 2016 (81) 145 60 months† 3.2 0 - 17.6 100 
Nanda et al., 2017 (82) 458 54 months‡ 5 22 31 35 - 
* The average time between primary operation and confirmation of recurrence 
† Median follow-up time 
‡ Mean follow-up time 
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mechanisms” (99, 102). This ratio is important as to establish the number of fractions and 
total dose needed to achieve tumour control whilst minimizing normal tissue toxicity. CNS 
cells have an accepted ratio of 2 Gy whilst meningiomas have a higher value 3.76 Gy (103, 
104). RT is planned and delivered via the conventional two-dimensional (2DRT), conformal 
three-dimensional (3DRT) or intensity-modulated (IMRT) techniques (105), and can be used 
in the following situations:  
• Meningiomas not amenable to surgery.  
• Following STR of benign meningiomas.  
• Following GTR/STR of atypical and anaplastic meningiomas.  
• Recurrent meningiomas.  
Location might preclude some meningiomas from resection and in such cases, RT offers an 
alternative option. One example is meningiomas of the skull-base, and particularly the 
cavernous sinus, which the internal carotid artery (ICA) and 4/12 cranial nerves traverse; 
namely the oculomotor, trochlear, trigeminal and abducens. Therefore meningiomas seated 
within the sinus present a surgical challenge and neurovascular outcomes could be 
unforgiving (106, 107). One previous paper reported on 28 treated cavernous sinus 
meningiomas of which 21 received primary 2DRT or 3DRT. Control rates were excellent with 
an 8-year PFS of 81% (108). A more recent report described outcomes following 3DRT in 53 
patients harbouring meningiomas; 28 as first-line treatment, and again control rates were 
impressive with a 10-year PFS of 95.8% (109). Mean doses in the two studies were similar: 
53.1 and 52.9 Gy respectively. Permanent morbidly such as persistent nerve palsies occurred 
in 3 patients across these two studies (7.1% versus (vs.) 1.9% respectively) which in addition 
to the improvement in PFS could theoretically reflect the betterment of RT techniques over 
the years.   
IMRT is an advanced technique of external beam radiation that aims to deliver precise 
treatment. This is achieved using the multi-leaf collimator (MLC). In IMRT treatment, the 
leaves of MLC move during radiation and thus ensure that the appropriate dose is targeted 
to treatment areas whilst sparing neighbouring normal tissue (110). Outcomes following 
IMRT are similar to those of 2DRT and 3DRT with local control rates ranging between 93% at 
5 years and 100% at 3 years. One series assessed IMRT in a population of 40 meningiomas; 
15 were prescribed it as definitive treatment. Fifteen percent of lesions were skull-based, 
and the median dose was 50.4 Gy. PFS at 5 years was 93% (111). Another series included 30 
patients treated for radiologically-diagnosed meningiomas of which mostly were situated 
along the sphenoid wings. Median dose was 57.6 Gy and after an estimated 23-month longer 
median follow-up period, five-year PFS was 94.8% (112). Although evidently yielding 
excellent results, it should be noted that on average, follow-up times in IMRT series are 
relatively shorter than those papers of conventional techniques (~34 vs. ~66 months) (108, 
109, 111-115). Therefore, studies with longer follow-ups are warranted. Grades 3 and 4 toxic 
effects (as classified by Radiation Therapy oncology Group (RTOG)) were observed in 4.5% of 
patients included (111, 112, 116).   
Meningiomas of the optic nerve sheath, which comprise <2% of intracranial meningiomas, 
also provide a significant body of literature regarding outcomes following RT. The reason 
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being that it has now become the primary treatment of choice, due to the high rates of 
surgery-associated blindness observed over the years (117). Overall, these studies 
demonstrate stability or regression in 95-100% of patients and prevention of visual 
deterioration in up to 96% of patients (118-120). 
RT could also be utilised following STR of benign WHO grade I meningiomas to attain better 
control rates. Previous case series demonstrated an adequate 10-year PFS off 77% and in 
other retrospective studies those rates following RT + STR were comparable to PFS rates 
following GTR (121). Of those, one study compared outcomes in 4 different treatment 
groups: Surgery alone (GTR, n=174 vs. STR, n=55), STR + RT (n=21), RT alone (n = 7) and 
radiosurgery alone (n = 5). Fifteen-year control rates for GTR and STR + RT were 76% and 87% 
respectively; much improved rates in comparison to 30% following STR alone (122). A more 
recent study has exhibited a similar pattern; the 5-year PFS rates in patients treated with GTR 
and STR + RT were 77 and 91%, respectively. Patients treated with STR alone had an inferior 
PFS rate of 38% (123). Those selected studies however are limited by their retrospective 
nature and by inclusion of patients across long periods of time (e.g. 1953-2001) which have 
witnessed marked changes in practices and WHO grading systems.  
The more aggressive nature of WHO grade II and III meningiomas means that adjuvant RT 
could potentially be necessary even following GTR. Several systematic reviews have 
addressed this topic and agreed on the following (97, 124, 125):  
• Anaplastic meningiomas should postoperatively receive RT regardless of EOR.  
• Atypical meningioma patients post STR should receive RT.  
• Atypical meningioma patients post GTR benefit from RT; however, the timing of 
administration could not be confidently defined considering the current evidence.  
Those reviews highlighted as a result the need for randomised controlled studies as to enable 
a better definition of RT timing for completely excised WHO II tumours. The ROAM/EORTC 
1308 and NRG-BN003 trials, which are currently in process of recruiting patients, should 
provide class I evidence on this issue (126, 127).  
Recurrence of meningiomas could indicate malignant transformation and a more aggressive 
course (128, 129). Thus, its management is challenging with a need to incorporate multiple 
treatment modalities, including RT. Evidence suggests better salvage rates with surgery + RT 
vs. surgery alone (130-132), however, meningiomas primarily treated with radiotherapy 
demonstrate resistance to re-irradiation and as a result further systemic therapies might be 
required (133); these are beyond the merit of the thesis and won’t be discussed.    
Other RT studies that are noteworthy include the NRG Oncology RTOG 0539 trial that has 
recently been published (134). This phase II study allocated patients to 1 of 3 prognostic 
arms: low risk, intermediate risk and high risk. The intermediate-risk group comprised of 
newly diagnosed WHO Grade II meningioma that had been treated with GTR or recurrent 
WHO Grade I meningioma. Recruitment ended in 2011 and 52 eligible patients were 
administered RT; 44 patients (84.6%) received IMRT and 8 (15.4%) received 3DRT. The 3-year 
actuarially PFS primary endpoint was 93.8%. The authors concluded that those results 
support the use of postoperative RT for newly diagnosed gross-totally resected WHO Grade 
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II or recurrent WHO Grade I meningioma irrespective of resection and that comparison with 
historical control data suggests it to be superior to active observation. This study although 
informative regarding an efficacious radiation protocol (total dose=54 Gy and number of 
fractions=30) lacks the comparative “observation” arm and thus the results of ongoing 
randomised controlled trials (ROAM and NRG-BN003) are needed to assess the efficacy of 
such protocols vs. active observation.  
1.8.1.2.2. RS  
The use of stereotaxy in neurosurgery goes back to 1908, when Sir Victor Horsley and Robert 
H. Clarke depicted the use of an apparatus to delineate cerebellar nuclei in monkeys (135). 
This apparatus was referred to as being “stereotactic”; a term they coined from the Greek 
words stereos meaning “3D”and taxis meaning “orderly arrangement”. This apparatus 
underwent multiple modifications the years after and in 1949, Professor Lars Leksell 
described an arc-based stereotactic system which he utilised in 1951 to introduce the 
concept of radiosurgery (136, 137). Leksell defined stereotactic radiosurgery (SRS) as “a 
technique for the non-invasive destruction of intracranial tissues or lesions that may be 
inaccessible or unsuitable for open surgery” (138). The principle of SRS treatment is cross-
firing of the target with narrow beams of radiation whilst surrounding normal tissue is 
spared. The succeeding years observed marked progress in techniques of delivery and now 
accessible for use are several technologies including Gamma Knife, Cyber Knife and other 
Linear Accelerator (LINAC)-based devices. These could be used to administer one single beam 
to lesions and this modality of treatment is known as SRS, however, if delivered over 
fractions, then it’s referred to as fractionated stereotactic radiotherapy (FSRT).  
The radiobiologic mechanisms underlining SRS and FSRT are quite different to those of 
conventional external beam radiotherapy (139). Additionally, whist the LQ model is still 
considered applicable for use in RT modalities of treatment, its utility in radiosurgical 
methods has been the topic of several studies which highlight its inappropriateness (140-
142), therefore, clinical outcomes following SRS and FSRT have been elected to be discussed 
separately in this thesis.  
A recent systematic review on the use of SRS in intracranial meningioma demonstrated an 
overall PFS between 78.0% and 98.9% at 5 years across 34 selected papers (143). The most 
commonly treated meningiomas were either grade I lesions (adjuvant) or radiologically-
diagnosed (primary). This indicates that atypical and anaplastic meningiomas, which tend to 
be infiltrative and uncircumscribed, might not be a suitable for SRS treatment. The majority 
of meningiomas selected for treatment were those located within the skull-base, which 
might have been inaccessible surgically or only could be subjected to STR. The median 
meningioma volume ranged between 3 and 17.5 cm3 and the weighted rate of toxicity was 
8.1%. A higher morbidity rate was observed among meningiomas >10 cm3. 
Patients with meningiomas >10 cm3 are thought to be safer undergoing FSRT. This could be 
conventionally planned and delivered in multiple daily fractions of 1.8-2.0 Gy or in a 
“hypofractionated” manner consisting of higher-dose fractions delivered over a fewer 
number of sessions. One report of 52 skull base meningiomas, measuring >4 cm in greatest 
dimension, demonstrated a 93% PFS at the median follow-up point of 42 months. Eighteen 
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(34.6%) received FSRT (total dose=50 Gy and number of fractions=30) after STR whilst the 
rest were treated for recurrence (n=34, 56.4%) (144). Histologically all meningiomas were 
classified as WHO grade I. Late toxic effects such as cranial nerve deficits were observed in 3 
patients (5.5%). Another study of outcomes in 136 patients with grade I meningiomas or a 
radiological diagnosis showed 5-year PFS to be likewise excellent at 93.8%. Median dose was 
56.95 Gy delivered in 30-33 fractions (145). No patients suffered from any serious late toxic 
effects however 51 (37.5%) showed grade 1 and 2 symptoms such as fatigue, headache and 
vertigo. 
Hypofractionated FSRT (hFSRT) regimens have also been the topic of recent investigations, 
which exhibited control rates between 89.4% and 100%. All meningiomas were located in the 
skull-base. Median follow-up time ranged between 24.5 and 53 months and sample size 
ranged from 22 to 143 (146-148). Example of a hypofractionated protocol as depicted by the 
previous three studies is 25-30 Gy over 3-5 fractions.   
A relative contraindication to all modalities of RS is the presence of peritumoural oedema, 
which has been shown to be an independent predictive factor of post-radiation oedema and 
consequent neurological symptoms (149).  
No studies have attempted to compare outcomes of RT and RS prospectively, however the 
excellent control rates demonstrated over the years have led the Clinical Commissioning 
Groups (CCG) of the National Health Service in England (NHS England) to issue a statement 
policy in 2013 (reference: NHS ENGLAND D05/P/e) on radiosurgical management of 
intracranial meningiomas. The policy describes indications for RS as well as clinical conditions 
that need to be met for the service to be NHS funded.  
1.8.1.3. Active monitoring strategy    
Not all meningiomas warrant an immediate intervention; for patients with minimally 
symptomatic small tumours who might suffer from multiple co-morbidities, an active 
monitoring strategy can be adopted (69). A meta-analysis of 22 retrospective studies 
amounting to 675 untreated meningiomas, of which 39% had symptoms on presentation, 
showed that the majority of meningiomas did not demonstrate any tangible growth over a 
median follow-up period of 4.6 years (150). However, the authors found tumour size to be a 
significant discriminating factor in that regard. Whilst 2.2% of meningiomas measuring <2 cm 
grew and went on to worsen or initiate symptoms, those measuring >2 cm, coupled with 
tumour signal hyperintensity; demonstrated an increased tendency to grow, but still again 
very few caused or worsened symptoms. The authors conclude by highlighting the need for 
systematic efforts to predict the disease progression during observation, which is what has 
been done in a recent retrospective study (151). Endpoints comprised:  
• Aggravation or development of neurological symptoms.  
• Significant tumour growth (absolute growth rate (AGR) ≥2 cm3/year or AGR ≥1 
cm3/year + relative growth rate ≥30%/year). 
• SRS becoming inappropriate if tumour volume exceeds 10 cm3 after observation. 
• Invasion of surgically-inaccessible spaces such as the cavernous and superior sagittal 
sinuses.  
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Two hundred and thirty-two patients were included in the analysis of which 32 exhibited pre-
existing neurological symptoms. After a median follow-up period of 46.9 months, 77 (33.2%) 
patients met at least one of the previous criteria and were subsequently deemed to have 
progressed. Predisposing factors included absence of calcification, hyperintense signal and 
larger tumours, in concordance with the findings of the meta-analysis, as well as pre-existing 
neurological symptoms. This of course puts the option of active monitoring for symptomatic 
tumours into question. However, similarly to previous studies reporting on outcomes of 
untreated meningiomas, the authors failed to incorporate important patient factors such as 
performance status (PS) and the presence of co-morbid conditions, which are likely to 
influence any management decision made. 
1.8.2. Asymptomatic incidental meningiomas 
As briefly aforementioned, the discovery of meningiomas whilst still asymptomatic is 
becoming a more frequently occurring phenomenon (152). Asymptomatic meningiomas 
diagnosed during radiological examination for unspecific symptoms or other diseases, are 
often referred to as “incidental meningiomas”. Incidental findings are frequently 
encountered in clinical settings, where patients presenting with headache, amongst other 
unspecific symptoms, undergo neuro-imaging which might reveal unrelated pathologies. An 
examination of 3000 CT scans carried out following head trauma found meningioma to be 
the most common incidental finding following cisterna magna (10% of findings) (153). 
Persisting audiovestibular symptoms such as tinnitus can also lead clinicians to request MR 
images of the brain, and again this could uncover a range of incidental findings including 
meningiomas (154, 155).  The increased use of brain imaging modalities for research also 
yields a significant number of Incidental neurological findings. The Rotterdam Scan study, the 
Alzheimer and Families study, and the Older Australian Twins study are all perfect examples 
of this with an average rate of 16.1% of incidental findings; meningiomas comprised 6.5-
26.0% of those (156-158). More epidemiological studies are soon to follow; these include the 
UK Biobank imaging study and the National Institutes of Health’s (NIH) BRAIN Initiative (159). 
An influx of incidental findings, including meningiomas, therefore is to be expected.  
Patients affected by such incidental findings have been previously described as Victims Of 
Modern Imaging Technology (VOMIT) in a personal view, highlighting the overwhelming 
anxiety that such discoveries are bound to generate (160). Nonetheless, whether in a 
healthcare or a research setting, qualitative data suggests that most individuals involved 
would like to be informed of these findings and from an ethical and a legal perspective, our 
duty is to do so (161, 162).  
Data also indicates that those individuals expect rapid access to experts as to be counselled 
about these findings (163), which in the case of incidental meningiomas would be a 
neurosurgeon, a neurologist or a clinical oncologist. 
A recent meta-analysis, comprising 9 articles, demonstrated how two meningioma factors, 
signal intensity and calcification status, could be used to guide individual patient 
management. For example, if a patient has meningioma calcification or a low T2 signal on 
MRI, a follow-up observation with neuroimaging and clinical monitoring can be preferentially 
considered. The follow-up interval can be as long as 6 months or 1 year. However, if the 
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imaging examination is less favourable in its characteristics, the possibility of rapid growth 
exists and as such, shorter intervals could be opted for. The latest meningioma guidelines, 
published by EANO and the National Comprehensive Cancer Network (NCCN), support this 
notion; however, EANO fail to define the optimum duration of follow-up whilst NCCN suggest 
indefinite surveillance, which clearly has economic implications (69, 164). Moreover, a recent 
survey of UK neurosurgery practice demonstrated that whilst most neurosurgeons 
considered patient factors and tumour location in optimising management, those previous 
radiological features were not taken into account as often (165).  This highlights the need for 
studies modelling growth patterns and subsequent management based on patient 
demographics, performance status, co-morbidity, as well as established radiological factors.   
1.9. Aims and outline of the thesis  
It is suggested that common incidental findings should be managed proportionately, 
sensitively, and economically (166).  The aim of this thesis is to devise a management strategy 
for incidental meningiomas which could inform clinical practice whist satisfying the first two 
factors. This will be presented in the form of 2 chapters with each encompassing a different 
study. Chapter 2 describes a systematic literature review of papers reporting incidental 
meningiomas and chapter 3 describes a retrospective cohort with the aim of modelling 
management strategies.  
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Chapter 2: Incidental Intracranial Meningiomas: A Systematic 
Review to Evaluate Management Strategies and Outcomes 
 
Acknowledgements: Dr Midhun Mohan (MM), academic foundation doctor at the University 
of Liverpool, was second reviewer and co-authored this chapter. Dr Richard Moon, academic 
foundation doctor at the University of Liverpool, co-authored this chapter.  
2.1. Introduction 
Meningiomas arise from the arachnoid cap cells in the linings of the brain (19). With an 
estimated annual incidence rate of five per 100,000 person-years in the UK, they account for 
almost a third of all primary intracranial neoplasms (2). Their incidence increases with age 
and peaks between the ages of 40 and 60 (167). The World Health Organisation (WHO) 
classifies these tumours into three groups: benign meningioma (grade I), atypical 
meningioma (grade II) and anaplastic meningioma (grade III) (19).   
Asymptomatic meningiomas constitute 30% of these tumours (168). In recent years, with the 
extensive application and noticeable advancement in neuroimaging modalities, incidental 
intracranial findings are becoming more prevalent (169). Meningiomas comprise 3.0-26% 
(153, 170-173). These incidental findings cause significant patient anxiety and distress which 
are compounded by the uncertainty faced by clinicians in their ongoing management.   
The management of incidental intracranial meningiomas consists of surgery, radiotherapy 
and active monitoring. Recent consensus guidelines published by the European Association 
of Neuro-Oncology (EANO) suggest active monitoring to be the best management strategy. 
However, the frequency and duration of follow-up are not specified (69). This leads to a 
variety of different follow-up strategies which has economic implications and is of uncertain 
patient benefit (165). 
Furthermore, there is a paucity in the literature with regards to outcomes following each 
management strategy. Thus, the aim of this systematic review is to evaluate the outcomes 
of current management strategies of incidental intracranial meningiomas with particular 
emphasis on active monitoring and the timing of meningioma progression during follow-up.  
2.2. Objectives  
The aim of this systematic review was to evaluate the outcomes of alternate strategies 
currently in clinical use for the management of incidental intracranial meningiomas.  
2.3. Methods 
This systematic review was conducted in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) statement (174). The protocol was 
registered with the international prospective register of systematic reviews (PROSPERO) 
under the following ID: CRD42017077928 (175).  
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2.3.1. Search strategy  
A literature search, last updated September 24, 2017, was performed from inception in the 
following electronic databases and study registries: 
i. Medline (Ovid): Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily 
and 1946 to Present. 
ii. Embase (Ovid): 1974 to present. 
iii. Cochrane Library: Central Register of Controlled Trials. 
iv. CINAHL Plus (EBSCO). 
v. World Health Organization – International Clinical Trials Registry Platform (WHO 
ICTRP).  
vi. UK Clinical Trials Gateway. 
The search strategy utilised for Medline (Ovid) and Embase (Ovid) can be found in Table 2.1. 
The strategy adopted for the other databases was altered appropriately and the search term 
“meningioma” was used in isolation to explore the study registries. 
Table 2.1. Search strategy for Medline (Ovid) and Embase (Ovid) 
Search Query 
1 exp meningioma/ 
2 
((central nervous system or CNS or brain* or cerebral* or intracranial or intra-cranial) adj3 
(cancer* or tumo?r* or malignan* or neoplas*)).mp. 
3 1 or 2 
4 
(glioma* or glial* or glioblastoma* or GBM* or astrocytoma* or ependym* or 
subependym* or neurocytoma* or pineal* or pineo* or chordoma* or hamartoma* or 
pituitary* or craniopharyngioma* or neuroblastoma* or medulloblastoma* or 
lymphoma* or metastat*).mp. 
5 
((lung* or breast* or skin* or blood* or h?ematolg* or dermatolog* or renal* or 
genitourinary*) adj3 (cancer* or tumo?r* or malignan* or neoplas*)).mp. 
6 (leuk?emia* or myeloma* melanoma*).mp. 
7 4 or 5 or 6 
8 3 not 7 
9 (asymptomatic or incidental or small or untreated).mp. 
10 
(surgery or radiotherapy or radiosurg* or observ* or conservative treatment or follow-up 
or natural history or growth).mp. 
11 8 and 9 and 10 
12 Limit 11 to English 
 
The bibliographies for each included record were scanned for additional studies that could 
have met the eligibility criteria.  
2.3.2. Paper selection 
Initially, the titles of all results were screened independently by AII and MM. Abstracts were 
reviewed with titles that mentioned Incidental/asymptomatic/small meningioma in 
combination with surgical/radiosurgical/radiotherapy/active monitoring outcomes or 
anything of similar construct. Full-text articles were inspected for abstracts which alluded to 
outcomes being available for more than 10 incidental/asymptomatic/small meningioma 
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patients. Decisions were blinded, and articles identified were only included upon mutual 
agreement; when disagreements occurred, authors discussed the disparities and attempted 
to resolve them. If these could not be resolved amongst AII and MM, the senior authors were 
consulted. Full-text article were subjected to the following population, intervention, 
comparison and outcomes (PICO) inclusion criteria outlined in Table 2.2.  
Relevant registered trials were categorised, based on recruitment status, into concluded or 
on-going. If concluded, disseminated results were examined. If yet to be disseminated, 
investigators were contacted for data involving incidental meningioma patients. On-going 
trials were excluded.  
Table 2.2 PICO inclusion criteria  
Population 
Patients ≥16 years of age diagnosed radiologically with an 
incidental/asymptomatic intracranial meningioma/s. NF2-associated and 
radiation-induced meningiomas were excluded. 
Intervention 
Surgical resection, SRS, FRT, active monitoring or hospital discharge after the first 
inpatient/outpatient appointment. 
Outcomes Primary Secondary 
 Post-intervention complications (surgery, SRS and FRT) Quality of life 
 Progression free survival (PFS) Neurocognitive function 
 Time to intervention (active monitoring)  
 Meningioma-related readmissions (hospital discharge)  
Duration of 
Follow-up 
≥12 months 
Study design  
Randomised controlled trials and retrospective and prospective case series and 
cohort studies with < 10 adult patients (≥ 16 years). Case reports were excluded 
2.3.3. Data Extraction 
A standardised pre-piloted proforma (appendix 1) was used to extract individual patient data 
per included study by AII and MM independently. In the event that a study’s population 
comprised in part of incidental meningiomas patients, corresponding authors of the studies 
in question were contacted via email to obtain their data. Data sets that subsequently 
remained incomplete were handled using the following imputation approach:  
i. Studies in which incidental meningioma patients comprised ≥90% of the cohort, 
weighted averages were quoted and used for quantitative analysis.  
ii. Studies with a lower percentage were excluded.  
Data was inputted into a Microsoft Excel for Window version 16.0 spreadsheet before being 
exported to SPSS version 24.0 for statistical analysis. 
2.3.4. Data synthesis  
Meningioma location was categorised into non-skull base and skull-base. Further 
subdivisions according to the Society for Neuro-oncology International Consortium on 
Meningioma (ICOM) classification system (unpublished material, appendix 4) was carried out 
when appropriate. Meningioma size was recorded as noted in each individual study. 
Volumetric measurements were converted to one-dimension diametric measurements using 
the equation Mean tumour diameter (MTD) = (2 × V) (1/3) and vice versa. Diametric 
measurements were used for prognostication whereas changes in tumour size over time 
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were performed using volumetry. Post-intervention complications and presenting symptoms 
were grouped into hierarchical domains where appropriate.  
2.3.5. Statistical analysis  
Data was analysed using SPSS version 24.0 (IBM, Armonk, NY, USA). Baseline patient 
demographics are expressed using descriptive statistics with non-weighted statistical 
differences for categorical variables assessed using the Chi-square test or Fisher’s exact test 
as appropriate. Continuous string variables were examined using the Mann-Whitney U test 
or Student’s t-test. Differences were considered to be statistically significant at 0.05. Pooling 
of raw individual patient data pertaining to all tested variables was carried out whenever 
possible and subsequent statistical significance was assessed on a non-weighted multivariate 
level.   
2.3.6. Quality assessment of the included studies 
Although all study types were eligible for inclusion, the literature available on this topic was 
observational and of retrospective nature. Therefore, the NIH Quality Assessment Tool for 
Observational Cohort and Cross-Sectional Studies was used (appendix 2, accessible using: 
accessible using: http://www.nhlbi.nih.gov/health-pro/guidelines/in-
develop/cardiovascular-risk-reduction/tools/cohort). This was carried out, independently, by 
AII and MM. Results were compared and in the case of discrepancies, the senior authors were 
asked to review before comparing results again.  
2.4. Results  
2.4.1. Literature search   
Fig. 2.1. shows the study selection process. The total number of unique pooled records was 
4750. Of titles screened, 4479 were deemed to be irrelevant and so were subsequently 
excluded. The abstracts of the remaining 271 records were screened and a total of 126 full-
text articles were examined for eligibility. The initial number of articles included and excluded 
was 20 and 95. The corresponding authors for an additional 11 records were contacted on 
21/11/2017. A duration of 3 months was allowed for responses and follow-up emails were 
sent to those expressing interest in providing data. However, none were received. Thus, the 
final number of articles included was 20. 
2.4.2. Study characteristics 
The characteristics of the 20 included studies are summarised in Table 2.3. Four of these were 
published prior to 2000 (176-179). All were retrospective observational studies (176-194) 
apart from one cross-sectional paper which investigated quality of life (QoL) and 
neurocognitive function (NCF) (195). Fifteen were single-centred studies whilst 5 were multi-
centred. There were no prospective observational or randomised controlled trials.    
2.4.3. Patient demographic and clinical characteristics  
The overall number of incidental meningioma patients was 2130. Eighteen studies 
comprising of 2061 (96.8%) patients were examined for quantitative analysis (176-192, 194). 
The remaining two studies, comprising 69 patients, were used for a narrative review of QoL 
and NCF (193, 195). Age was reported in 12 studies for a combined total of 814 (39.5%) 
patients. The mean age was 63.1 years (SD = 6.9). Sex was reported in all studies with 1531 
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being female and 399 males (4:1). Co-morbidities and performance status were noted in only 
one study. Baseline clinical features are summarised in Table 2.4.   
2.4.4. Baseline radiological characteristics  
Indications for brain imaging were neurological deficit (n=107), headache (n=101), 
audiovestibular symptoms (n=88), head injury (n=77) and miscellaneous (n=163). These 
symptoms were all deemed unrelated to the meningiomas discovered. Thirty-two 
meningiomas were identified during follow-up for other diseases, while 97 were found on 
voluntary imaging or routine health check-ups. Reasons for scan were not reported for the 
remaining 1385 (67.2%) patients. Location was available for 1465 meningiomas of which 
69.1% were non-skull base. The mean diameter for 888 meningiomas was 2.14 cm. The 
remainder of baseline imaging characteristics are outlined in Table 2.4.  
2.4.5. Treatment groups  
At initial presentation, four management strategies were identified; surgery, stereotactic 
radiosurgery (SRS), clinical-radiological active monitoring and clinical active monitoring. 
Eleven patients were discharged without clinical or radiological data and thus were excluded 
from subsequent analysis. The two active monitoring strategies aforementioned were 
combined. Five hundred and sixty (27.3%) patients had surgery, 450 (22.0%) had SRS while 
1040 (50.7%) patients were conservatively managed with regular clinical or clinical-
radiological monitoring. The differences in characteristics amongst the three management 
groups are summarised in Table 2.3.   
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.1. The study selection process  
20 
 
 
  
 
 
21 
 
 
  
22 
 
2.4.6. Treatment outcomes 
2.4.6.1. Active monitoring  
2.4.6.1.1. Follow-up regimens 
Fifteen studies included patients who were subjected to active monitoring, of which only six 
described their follow-up regimens; endpoint being intervention or death. A maximum 
follow-up duration for patients who did not experience radiological or clinical progression 
was not stated. Study-specific follow-up protocols are described in Table 2.5.  
Table 2.5. Active monitoring protocols per studies included 
Study  Timing of scan following diagnosis 
Olivero et al., 1995 (179) 3 months → 9 months →1 to 2 yearly 
Nakamura et al., 2003 (182) 6 months → 1 yearly  
Sonoda et al., 2004 (183) 3 months → 6 monthly  
Jo et al., 2010 (187) 6 months →1 to 2 yearly 
Jadid et al., 2014 (9) 1 yearly for a minimum of 10 years 
Liu et al., 2015 (191) 3-12 monthly  
 
2.4.6.1.2. Radiological and clinical progression  
Clinical and radiological data were available for 1040 patients. Follow-up times were reported 
for 683 patients, with a mean of 49.5 months (SD=29.3). During follow-up, 235/1040 (22.6%) 
meningiomas grew, according to each study-specific criterion for growth (outlined in Table 
2.6). Time-to-first-evidence-of-radiological-progression was reported for 69 (29.4%) patients 
at a mean of 28.5 months (SD=7.54). Considering the heterogeneity of growth definitions, a 
decision was made not to pool data for subsequent comparisons of growing versus non-
growing meningiomas. 
 
 
 
 
 
For 432 patients, symptom development (yes/no) was not reported. Out of the remaining 
608 patients, 66 (10.9%) patients developed symptoms. These encompassed seizure (n=8), 
motor deficit (n=6), cognitive deficit (n=3), visual deficit (n=2) and cranial nerve palsy (n=2). 
The nature of the symptoms was not stated in the remaining 45. Differences in baseline 
characteristics amongst patients who developed symptoms and those that did not are 
outlined in Table 2.7.   
2.4.6.1.3. Intervention endpoints and timeframe for treatability  
Intervention was recommended or carried out in 220 (21.2%) patients. Indications for 
treatment were radiological progression (n=153), development of symptoms (n=66) and 
patient preference (n=1). Surgery was performed in 179 whilst SRS was the intervention of 
choice in the remainder (n=30, 14.2%). Two patients were subject to surgery and adjuvant 
Table 2.6. Meningioma growth definitions by included studies 
Study  Measurement  Definition 
Go et al., 1998 (177) Diameter ≥0.5 cm 
Niiro et al., 2000 (180) Diameter ≥0.5 cm 
Yoneoka et al., 2000 (181) Volume >1 cm3/year 
Hashiba et al., 2009 (186) Volume >15% 
Jo et al., 2010 (187)  Volume >25% 
Jadid et al., 2014 (9) Diameter >0.2 cm 
*Seven studies lacked a definition for growth whilst 2 did not clearly define it 
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SRS. Mean time-to-intervention, available for 175 patients, was 24.8 months (SD=18.2); 
94.3% were carried out within five years of diagnosis whilst 5.7% received an intervention 
after 5 years, latest being performed 88 months following diagnosis. Differences in baseline 
characteristics amongst patients who had an intervention and those who did not are outlined 
in Table 2.7.  
Table 2.7. Differences in baseline characteristics based on symptom development and intervention 
  Symptom development  Intervention  
Factor  Yes No P Yes No P 
Age (%) <65 yrs. 37 (13.7) 233 (86.3) 0.032 135 (39.1) 210 (60.9) <0.001 
 ≥65 yrs.  23 (8.0) 263 (92.0)  34 (11.4) 264 (88.6)  
Sex (%) F 39 (9.3) 382 (90.7) <0.001 166 (21.4) 609 (78.6) <0.001 
 M 27 (21.6) 98 (78.4)  54 (38.0) 88 (62.0)  
Location (%) Non-skull base 48 (11.3) 376 (88.7) 0.455 146 (31.7) 315 (68.3) 0.059 
 Skull base 18 (13.7) 113 (86.3)  42 (24.0) 133 (76.0)  
Diameter 
(%) 
<3.0 cm 51 (9.7) 476 (90.3) <0.001 164 (27.3) 437 (72.7) 0.564 
 ≥3.0 cm 15 (42.9) 20 (57.1)  11 (23.4) 36 (76.6)  
Signal 
intensity (%) 
Hyperintense 11 (16.7) 55 (83.3) 0.032 13 (16.9) 64 (83.1) 0.116 
 Iso/ 
hypointense 
4 (5.4) 70 (94.6)  10 (9.2) 99 (90.8)  
Calcification 
(%) 
Yes 20 (10.7) 167 (89.3) 0.134 48 (25.3) 142 (74.7) <0.001 
 No 45 (15.5) 245 (84.5)  128 (43.1) 169 (56.9)  
Peri-
tumoural 
oedema (%) 
Yes 52 (36.9) 89 (63.1) <0.001 115 (82.7) 24 (17.3) <0.001 
 No 14 (5.1) 260 (94.9)  55 (17.4) 261 (82.6)  
 
2.4.6.1.4. Relationship between baseline radiological characteristics, growth dynamics and 
symptom development 
Raw patient data was available for 137, 89 (8.56%) of whom had known symptom status by 
the end of follow-up; mean duration was 39.7 months (SD=27.7). Seventeen patients 
developed symptoms while 72 remained asymptomatic. Average follow-up time did not 
differ between the two groups (41.6 vs. 39.2 respectively, p=0.753). Differences in 
radiological characteristics are shown in Table 2.8. A binary logistic regression model was 
used for analysis. Factors that were significantly associated with symptom development were 
an initial meningioma diameter ≥3.0 cm (OR=37.5 [95% CI=7.57-185.8), p=0.005) and the 
presence of peritumoural oedema (OR=4.25 [95% CI=1.06-16.9], p=0.21). The absolute 
growth rate (AGR) of meningiomas measuring ≥3.0 cm was 4.0 cm3/yr. compared to an AGR 
of 0.62 cm3/yr. in meningiomas <3.0 cm (p<0.001).  
2.4.6.2. Surgery 
Overall, 741/2050 (36.1%) patients had surgery. Five hundred and sixty were operated at 
initial presentation whilst 181 had a period of active monitoring prior to surgical intervention.  
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2.4.6.2.1. Extent of resection  
Extent of resection, as described in each study, was reported for 300/741 (40.5%) patients. 
GTR was achieved in 285 (95.0%) whereas STR was performed in the remaining 10 (5.0%) 
patients. Two patients required adjuvant SRS. 
 
2.4.6.2.2. Histopathology and recurrence  
Histology reports were available for 316 patients. Three hundred and three (95.9%) had 
benign WHO grade I meningiomas, 10 (3.16%) had atypical WHO grade II whilst in 3 (0.95%) 
the pathology revealed anaplastic WHO grade III. Reclassification of these meningiomas 
according to the 2016 WHO system for brain tumours was not feasible. There was no tumour 
recurrence observed in 105 patients during a mean follow up time of 20 months (SD=14.2). 
Recurrence status was not reported for the remaining.  
2.4.6.2.3. Post-operative morbidity and mortality 
From a total of 533/741 (71.9%) patients with available post-operative morbidity data, 88 
(15.0%) had complications which were neurological in 47 (53.4%), surgical in 28 (31.8%) and 
13 (14.8%) patients had medical complications. Mortality data was not available. 
Performance status post-surgery was reported in 168 patients. Scales used were Karnofsky 
performance score (KPS) (n=5) and the Glasgow Outcomes Scale (GOS) (n=163). Four patients 
assessed by KPS scored 100 whereas 1 patient scored 50. For patients assessed with GOS, 
156 (95.7%) patients had a score of 4-5 and four (2.45%) had a score of 1-3. Seven patients 
were reported to have a score of less than 5.  
2.4.6.3. SRS 
SRS was the initial treatment of choice in 450 patients. Thirty patients were subjected to 
active monitoring and subsequently underwent SRS due to clinical or radiological 
progression.  
Table 2.8. Growth dynamics and symptom development stratified by baseline characteristics 
Factor  
Mean 
AGR 
(cm3/yr.) 
P 
Mean 
RGR 
(%/yr.) 
P 
Symptom 
development, 
yes/total (%) 
BLR P 
Location Non-skull base 2.14 0.942 53.8 0.213 12/64 (18.8) 0.927 
 Skull base 1.79  30.5  5/25 (20.0)  
Diameter <3.0 cm 0.62 <0.001 27.3 0.863  2/62 (3.2) 0.005 
 ≥3.0 cm 4.00  28.4  15/27 (56.6)  
Signal 
intensity 
Hyperintense 2.04 0.988 53.0 0.262 11/41 (26.8) 0.242 
 Iso/ 
hypointense 
2.02  36.1  4/27 (14.8)  
Calcification Yes 1.35 0.499 60.6 0.093 6/25 (24.0) 0.768 
 No 2.42  38.0  10/47 (21.3)  
Peritumoural 
oedema  
Yes 0.34 0.301 55.4 0.727 5/10 (50.0) 0.021 
 No 2.32  44.7  12/63 (19.0)  
Abbreviation: AGR=annual growth rate; RGR=relative growth rate; BLR=binary logistic regression 
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2.4.6.3.1. SRS treatment parameters  
Two studies provided data regarding radiosurgical parameters. Median marginal dose was 
14.5 Gy in 1 study and 13.0 Gy in the other. A prescription isodose line of 50% was noted in 
one study.  
2.4.6.3.2. Response rates post SRS 
Radiological response was available for 389/480 (81.0%) patients. Three hundred and eighty-
two (98.2%) meningiomas remained stable as opposed to 7 (1.80%) which demonstrated 
progression during follow up. The mean follow-up time was 40.9 months (SD = 14.6). 
Adjuvant SRS was performed in 2 surgery patients for whom progression was not reported.  
2.4.6.3.3. Post SRS complications  
No data was available for 91 patients. Of the remaining 389, 304 (78.1%) did not have post-
SRS morbidity. Eighty-five (21.9%) patients had the following complications: headache 
(n=22), epilepsy (n=11), motor deficit (n=6), scalp paraesthesia (n=6), alopecia (n=5), 
dizziness (n=5), ocular pain (n=4) and tinnitus (n=4). Twenty-two patients suffered from 
asymptomatic peritumoural oedema.  
2.4.7. Meningioma specific mortality  
Two patients died as a result of their meningiomas. A 73-year-old male exhibited significant 
tumour growth at 9 and 12 months following diagnosis and thus surgery was recommended. 
The patient refused surgery. Consequently, the patient suffered large intracerebral and 
subdural haemorrhages and died. The post-mortem revealed an angioblastic meningioma, 
more recently defined as hemangiopericytoma. The second patient was a 74-year-old male 
who died 88 months following diagnosis. His meningioma grew from 4.5 to 8.2 cm and 
subsequently was offered surgery however he declined any intervention. 
2.4.8. QoL and NCF outcomes 
One cross-sectional study examined NCF and QoL in 21 patients with stable radiologically-
suspected asymptomatic meningiomas and compared them to a matched healthy population 
(195). Mean age was 63.4 years. Four were male and 17 were female. Meningioma patients 
fared worse compared to healthy controls on working memory and motor speed. However, 
there was no correlation between these findings and radiological characteristics such as 
tumour location and size. The investigators used the Short Form (36) health survey (SF-36) to 
assess QoL. The meningioma cohort had lower scores on 2/8 domains namely vitality and 
general health.  A retrospective study comprising of 48 meningioma patients (median age 80 
years, 32 females: 16 males), utilising a different battery of NCF measures, found no 
differences in outcomes compared to a matched population (193). However, when stratified 
by tumour location, patients with infratentorial meningiomas performed worse on memory 
and verbal fluency tests. Patients in both studies were treatment-naive. No studies examined 
the effect of surgery or SRS on NCF and QoL in incidental meningioma.  
2.4.9. Quality assessment results 
Quality assessment results are summarised in Table 2.8. Ten studies were rated as “good”, 
eight were “fair” and 2 were deemed to be of “poor” quality. No discrepancies were found 
between the results of AI & MM. All studies mutually failed to report relevant information 
needed to answer questions 6, 10 and 12 (see appendix 2).  
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Table 2.9. Results of the Quality assessment performed for all studies included  
Study 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Score 
Firsching et., 
1990 (176)  
+ - NA + NA NR + - + NR + NR + - Fair 
Olivero et al., 
1995 (179) 
+ + NA + NA NR + - + NR - NR + - Fair 
Go et al., 1998 
(177) 
+ + NA - NA NR + + - NR + NR + - Fair 
Nishizaki et al., 
1999 (178) 
+ + NA + NA NR + + + NR + NR + - Fair 
Niiro et al., 
2000 (180) 
+ + NA + NA NR + + + NR + NR + - Good 
Yoneoka et al., 
2000 (181) 
+ + NA + NA NR + + + NR + NR + + Good 
Nakamura et al., 
2003 (182) 
+ + NA + NA NR + + + NR + NR + - Good 
Sonoda et al., 
2004 (183) 
+ + NA - NA NR + - - NR + NR + - Fair 
Yano et al., 
2006 (185)  
+ + NA + NA NR + + - NR + NR + - Good 
Reinert et al., 
2006 (184) 
+ + NA + NA NR + + + NR + NR + - Good 
Hashiba et al., 
2009 (186) 
+ + NA + NA NR + + + NR + NR + + Good 
Jo et al., 2010 
(187)  
+ + Na + NA NR + - + NR - NR + - Fair 
Rubin et al., 
2011 (194) 
+ + NA + NA NR + + - NR - NR + - Fair 
Kasuya et al., 
2012 (188) 
+ - NA - NA NR - - - NR - NR + - Poor 
Van 
Nieuwenhuizen 
et al., 2013 
(195) 
+ + - + NA NR + + + NR + NR NA + Good 
Hoe et al., 2015 
(189) 
+ - NA + NA NR + + + NR + NR + + Good 
Jadid et al., 
2015 (9)  
+ + NA + NA NR + + + NR - NR + - Fair 
Liu et al., 2015 
(191) 
+ + NA + NA NR + - - NR - NR + - Poor 
Zeng et al., 2015 
(192) 
+ + NA + NA NR + + + NR + NR + + Good 
Butts et al., 
2017 (193)  
+ + NA + NA NR + + + NR + NR + + Good 
NA=not applicable, NR=not reported 
List of 14 questions is available in the appendix 
 
2.5. Discussion 
2.5.1. Summary of review aims  
This systematic review was conducted with the aim of evaluating the alternate strategies 
(active monitoring, surgery or SRS) currently in clinical use for the management of incidental 
meningiomas.  
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2.5.2. Summary of key findings 
Eighteen retrospective studies were identified for quantitative analysis, comprising a final 
cohort of 2061 patients. At initial presentation around half of these patients (51%) were 
managed conservatively with active monitoring, 27% of patients underwent surgical 
resection and 22% of patients were treated with SRS. Eleven patients were discharged 
without any available clinical or radiological data. 
Of patients subjected to active monitoring, 1 in 5 went on to receive either surgical or 
radiological treatment of their meningioma, with the majority undergoing surgery. The 
average time from diagnosis to intervention within the active monitoring cohort was two 
years, with 94% of patients treated within 5 years.  
The overall intervention rate within the entire study cohort was 59%.  Neurological, surgical 
and medical complications were encountered by 15% of patients undergoing surgery and 
22% of patients receiving SRS. A histological diagnosis of Grade I meningioma was recorded 
for 96% of operated meningioma patients. 
2.5.3. Active monitoring strategies  
Active monitoring strategies for the management of incidental meningioma are becoming 
increasingly more common (152), with recent neuro-oncology guidelines advocating their 
use in patients demonstrating no clinical symptoms and no accompanying radiological mass 
effect (69). However, while the guidelines recommend annual clinical and MRI tests after an 
initial observation period of 6 months, they do not provide advice as to the length of follow 
up for patients that do not experience clinical or radiological progression. Moreover, while 
the development of clinical symptoms is a clear indication for treatment, no consensus exists 
as to what constitutes significant radiological progression and when it may necessitate 
intervention. 
Our results show that of those patients with recorded presence/absence of symptoms, 11% 
reported subsequent symptomatic development. Predictive factors on univariate analysis 
were male gender, tumour diameter ≥3.0 cm and the presence of peritumoural oedema. 
Both radiological factors remained significant on multivariate analysis. 
As noted, there is no current agreement on the definition of significant radiological 
progression. Three different strategies emerged from our results: i) absolute increase in 
maximum diameter, ii) absolute increase in tumour volume, iii) relative percentage increase 
in tumour volume. Furthermore, it was evident that the time course over which tumour 
growth occurred was poorly documented, with only one study assessing annual change (181). 
Relative and absolute annual growth rates were analysed for meningiomas with a maximum 
diameter greater or less than 3 cm. It was apparent that no significant difference was present 
in the relative growth rate (%/year) between the cohorts. However, absolute growth rates 
(cm3/year) were noted to be significantly different. Those meningiomas with a maximum 
diameter >3 cm demonstrated a higher annual growth rate and were also correlated with a 
greater incidence of new symptom development. This may suggest the use of absolute 
growth rate as a more clinically relevant measure of radiological progression. Although only 
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available for a limited number of patients, the average time to radiological progression was 
28.5 months. 
A large degree of heterogeneity was similarly observed in the active monitoring regimens. 
The timing of the first scan ranged from 3 to 12 months with a subsequent frequency of 
follow-up scans varying from 6 months to 2 years. It is worth considering the impact of this 
variation in imaging protocols on the recorded time to radiological progression. Only one 
study commented on the duration of monitoring of patients with no clinical or radiological 
progression, with a recorded minimum of 10 years or until patient death (9).  
2.5.4. Alternative management strategies 
At initial presentation, if not undergoing an active monitoring management strategy, patients 
were treated with either SRS or surgery. Twenty-seven percent of patients underwent 
surgery at the time of initial diagnosis, with 22% of patients receiving SRS. The overall 
intervention rate at initial presentation was 49%.  
2.5.5. Treatment interventions 
Active monitoring endpoints necessitating further intervention were defined as either clinical 
or radiological progression. Radiological progression was evident in 235 (22.6%) patients 
within the active monitoring cohort. Of these, 66 patients also reported concurrent symptom 
development. Two hundred and twenty patients subsequently received or were 
recommended to receive a therapeutic intervention. The mean time to intervention was two 
years, with over 9 out of 10 patients receiving their treatment within 5 years of diagnosis of 
incidental meningioma. Of these patients failing active monitoring strategies, 82% 
underwent surgical resection of their meningioma. 
Of the available histology reports for patients undergoing surgical resection at any time point, 
96% received a diagnosis of WHO grade I meningioma. No tumours were reported to be 
metastatic lesions radiologically misinterpreted as a meningioma, suggesting that an early 
scan at 3 months is not necessary to rule out metastatic disease. 
The post-operative complication rate was reported as 15%, as compared to 22% for patients 
receiving SRS. This is comparable to the complication rates reported in the literature for 
operative and radiosurgical treatment of symptomatic meningiomas (143, 196, 197). 
2.5.6. Recommendations 
2.5.6.1. Clinical implications  
We found that only 20% of patients undergoing active monitoring regimes demonstrated 
radiological or clinical progression requiring a treatment intervention. This confirms the 
validity of active monitoring strategies and supports the current EANO guidelines. However, 
it is apparent that within this data set only half of patients were subject to active radiological 
monitoring. Following the recent publication of these guidelines, we would envisage the 
proportion of patients undergoing an immediate intervention is likely to reduce. 
This data shows that disease progression during active monitoring and subsequent treatment 
intervention in the vast majority of cases occurs within 5 years of diagnosis. Given the current 
lack of consensus on the necessary duration of active monitoring, this may suggest that for 
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those patients not displaying evidence of radiological and/or clinical progression, imaging 
surveillance beyond a 5-year time point may be less frequently required or unnecessary 
depending on individual patient demographics including comorbidity and performance 
status. 
The data also suggests that meningiomas measuring more than 3 cm in greatest diameter 
and those with peritumoural oedema are at a higher risk of symptomatic development. 
Patients with these features should therefore be more rigorously monitored within the first 
5 years of diagnosis.  
2.5.6.2. Future research  
It is evident from this data that there are a wide variety of measurements of growth reported 
in the literature. A uniform definition of growth is therefore required for ongoing clinical 
management and future research.  
Furthermore, the current heterogeneity in the frequency of radiological surveillance requires 
a unified strategy in order to better identify radiological progression, limit radiation exposure 
and reduce the costs to health care.   
For patients at high risk of meningioma growth, it is unclear when the optimal timing for 
intervention is. A cost-effectiveness analysis comparing early and delayed treatment would 
help inform this decision.  
All studies in this review were retrospective in nature and largely single-centre. There is a 
clear need for the establishment of a validated core outcome set for data standardisation 
and its subsequent use in prospective multi-centre studies investigating the management 
and outcomes of incidental meningiomas. 
2.5.7. Comparisons to published review articles 
There are only two systematic reviews published assessing the outcomes of incidental 
meningiomas. One review assessed the risk factors for development of new or worsened 
symptoms during follow up of untreated symptomatic and asymptomatic meningiomas, 
concluding that patients with bigger meningiomas are more likely to become symptomatic; 
a finding which we replicated (150). Low tumour growth was associated with low T2 signal in 
the other review which attempted to meta analyse the presence or absence of tumour 
growth during follow-up (10). Our data demonstrated that high T2 signal was associated with 
symptom development which may have resulted from tumour growth.  
2.5.8. Study limitations 
This study has several limitations. Firstly, raw data was not available for all studies, which 
were also of a poor level of evidence base. The heterogeneity of the available data prevented 
meta-analysis and descriptive analyses performed were not weighted to account for pooling 
from multiple investigations. The studies included in this review spanned a 27-year time-
frame. During this period, significant advances in operative and radiological technology, post-
intervention outcomes and management guidelines (including the WHO classification 
system) occurred, thus introducing confounding variables into our data.  
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The lack of stratification of complication rates between surgery at the time of initial 
presentation or on encountering disease progression during active monitoring prevented a 
detailed analysis of post-treatment outcomes. 
2.6. Conclusion  
Incidentally-diagnosed asymptomatic meningiomas are common with no clear consensus on 
optimal management strategies. This review demonstrates a wide variety in current practice 
of radiological surveillance but suggests that the majority of patients who develop clinical or 
radiological progression will do so within the first 5 years of diagnosis. Regular monitoring 
may therefore be less frequently required beyond this time point.   
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Chapter 3: Incidental Meningioma: Prognostic Analysis Using 
Patient Comorbidity and MR-Tests (The IMPACT Study) 
 
Acknowledgements: Dr Midhun Mohan (MM), academic foundation doctor at the University 
of Liverpool, was second observer for assessment of inter-observer variability of radiological 
factors.  
3.1. Introduction 
The increased access to various modalities of brain imaging including MR and CT for clinical 
and research purposes has led to an exponential increase in the number of incidental findings 
with meningiomas comprising a significant fraction (173, 198-200). International guidelines 
suggest active radiological and clinical monitoring as the modality of choice for managing 
these tumours (69, 201), however lack of details surrounding the optimal duration of follow-
up and intervals in-between scans highlights the paucity of high-quality studies addressing 
this issue. Quite a number of investigations have identified prognostic radiological factors 
which increase the risk of meningioma growth and subsequent clinical symptoms (10, 202). 
However, the timing of such progression is poorly defined. Moreover, clinical factors such as 
performance status and patient comorbidity remain unexplored in relation to prognosis of 
incidental meningiomas.  
The understanding of such factors’ prognostic implication is essential to risk stratification of 
incidental meningioma patients.  Each stratum could be assigned a management strategy 
which reduces the health cost burden of these incidental findings and improves the overall 
clinical practice.  
In this study, we used data for individual patients from a retrospective incidental meningioma 
cohort to develop a prognostic model for the risk of disease progression during active 
monitoring, and to assess the role of patient demographics and MR characteristics in this 
prediction. The model was internally validated using a bootstrapping approach enabling 
assessment of its predictive ability.  
3.2. Objectives  
3.2.1. Primary objective  
Develop a prognostic index to predict the risk of disease progression during active monitoring 
for incidentally-discovered asymptomatic meningioma.  
3.2.2 Secondary objectives 
• Establish the most common scenarios that lead to the identification of incidental 
meningiomas. 
• Delineate the histological and pathological characteristics of tumours subjected to 
surgical intervention. 
• Establish growth rates of incidental meningiomas.  
• Measure the rate of post-intervention complications and tumour recurrence/growth; 
both could help inform clinical practice in terms of choosing an intervention.  
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3.3. Methods  
This study was approved by the clinical audit group of the Walton Centre NHS Foundation 
Trust on 19th April 2017 (appendix 3). Patients who underwent surgery were consented to 
the Walton Research Tissue Bank (North Wales REC No 11/WNo03/2). All tissue, imaging and 
clinical information were available for use under that ethics approval. 
3.3.1. Study design 
A retrospective cohort analysis of asymptomatic meningioma patients identified incidentally.  
3.3.2. Study Setting   
This retrospective study involved patients seen in the Departments of Neurosurgery and 
Neurology at a tertiary centre: the Walton Centre NHS Foundation Trust, Liverpool, UK, 
between 1st January 2007 and 31st December 2015.  
3.3.3. Participants 
Patients 16 years of age or older with a newly identified incidental meningioma were 
included. Radiation-induced and NF2-associated meningioma patients were excluded. 
Eligible patients were identified using the Computerised Radiological Information System 
(CRIS) search tool. The search terms utilised were “meningioma”, “incidental” and “incidental 
meningioma”. The two lists of patients obtained from searching "incidental" and 
"meningioma" were combined and only duplicates (patients that appeared on both lists) 
were maintained whereas unique records were discarded. One unique record for each 
patient was subsequently kept. The list acquired from the search using “incidental 
meningioma” was cross-checked against patients obtained from the first search strategy to 
ensure they all featured. These steps were performed in Microsoft Excel for Windows version 
16.0. 
3.3.4. Variables and data sources 
• Patients’ demographics. Data source: medical records. Factors recorded included age, 
sex, WHO PS (Table 3.1) and the age-adjusted Charlson comorbidity index (ACCI) (Table 
3.2). History of malignancy, type and status (in-remission /active) were also recorded. 
Active malignancies included those undergoing treatment, those identified and awaiting 
treatment, and patients with evidence of clinical or radiological disease progression. In-
remission status was assigned to those who had finished their scheduled treatment with 
no succeeding clinical or radiological evidence of progression, regardless of time.     
• Indication for carrying out brain CT/MRI which led to the identification of a meningioma, 
these reasons had to be unrelated to the tumour itself. Data source: medical records. 
• Radiological data. Data source: Carestream Vue picture archiving and communication 
system (PACS), version 11. Factors recorded included number of meningiomas, 
calcification status on non-contrast CT (diffuse/partial/absent), MRI field strength, 
tumour signal intensity compared to the contralateral grey matter on MRI T2/FLAIR 
(hypo/iso/hyper), peritumoural oedema in relation to tumour volume using the signal 
change present on MRI T2/FLAIR (0-5%/6-33%/34-66%/67-100%; based on the Visually 
AcceSAble Rembrandt Images [VASARI] MR features for gliomas(203)), maximum 
meningioma diameter on gadolinium-enhanced axial MRI T1 (A), diameter perpendicular 
to A (B), maximum height on coronal/sagittal gadolinium-enhanced MRI T1 (C). 
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Meningioma volume was calculated using the ABC/2 formula. Meningioma location was 
classed into non-skull base and skull base and further subcategorised according to the 
Society for Neuro-oncology International Consortium on Meningioma (ICOM) 
classification system (unpublished material, appendix 4). Meningiomas in proximity of 
the major dural venous sinuses (superior sagittal sinus [SSS]/transverse sinus 
[TS]/sigmoid sinus [SS]/cavernous sinus [CS]/the confluence of sinuses) were categorised 
as separate, in direct contact or invading. Contact with critical neuro-vascular structures 
(i.e. ICA, optic apparatus [OA]) was noted. Meningiomas that fulfilled one of the two 
previous categories were said to be in proximity of critical neurovascular structures. Any 
other intracranial pathologies were also noted. Fig. 3.1. depicts how certain radiological 
characteristics were classified.  
Table 3.1. WHO performance status 
classification 
Table 3.2. Age-adjusted Charlson comorbidity 
index (204, 205) 
Score Description Condition   weight 
0 
able to carry out all normal 
activity without restriction 
Age (years) <50 0 
1 
Restricted in strenuous activity 
but ambulatory and able to carry 
out light work 
 50-59 1 
2 
Ambulatory and capable of all 
self-care but unable to carry out 
any work activities; up and about 
more than 50% of waking hours 
 60-69 2 
3 
Symptomatic and in a chair or in 
bed for greater than 50% of the 
day but not bedridden 
 70-79 3 
4 
Completely disabled; cannot 
carry out any self-care; totally 
confined to bed or chair. 
 ≥80 4 
5 Dead Myocardial infarction  1 
 Congestive heart failure   1 
Peripheral vascular 
disease 
 1 
Hemiplegia  2 
Cerebrovascular disease  1 
Pulmonary disease  1 
Diabetes   1 
 With end 
organ 
damage 
2 
Renal disease  2 
Liver disease Mild 1 
 Severe 3 
Peptic ulcer disease   1 
Cancer   2 
 Metastatic 6 
Dementia   1 
Connective tissue disease  1 
AIDS  6 
Hypertension   1 
Skin ulcers/cellulitis   2 
Depression  1 
On Warfarin   1 
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• Management plan agreed upon following identification of an incidental meningioma 
(active monitoring/surgery/SRS/FSRT/hospital discharge) and the responsible physician 
(neurosurgeon/neurologist/clinical oncologist). Data source: medical records.     
• Active monitoring defined as regular surveillance imaging and outpatient clinical 
observation. Data source: medical records and PACS. Recorded factors included: number 
of scans, and interval between them (months). For each scan the following was noted: 
imaging modality (CT/MRI and field strength), peritumoural signal intensity, venous sinus 
involvement, meningioma volume and any new intracranial pathologies. Each scan was 
examined alongside its corresponding outpatient clinic appointment for any evidence of 
meningioma-related neurological symptoms 
Fig.3.1. (A-C) Non-contrast axial CT scans demonstrating the 3 levels of meningioma calcification (circle). (A) 
Diffuse calcification. (B) Partial calcification. (C) Absence of calcification. (D-F) T2 MR axial sequences showing the 
3 levels of tumour intensity (circle). (D) Hypointense. (E) Isointense. (F) Hyperintense. (G-I) T1-weighted MR with 
gadolinium (contrast) showing the relationship between the meningioma and the nearby venous sinus (SSS). (G) 
Separate as there’s no clear attachment to the sinus wall. (H) In direct contact with the lateral wall of the sinus. 
(I) Clear macroscopic distortion and invasion of the sinus.  
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(motor/sensory/language/cognitive/seizure/headache/other). Each appointment’s 
outcome was recorded (resume follow-up/surgery/SRS/FSRT/hospital discharge).  
• Intervention details if performed, indication for intervention 
(radiological/clinical/patient preference) and time-to-intervention. Data source: medical 
records.   
- Surgery: Simpson score (as recorded by the surgeon in the operative notes), 
WHO grade (reclassified according to the WHO 2016 system), histological 
subtype, postoperative medical and surgical complications (Landriel-Ibañez 
Classification (206)), postoperative WHO PS, postoperative follow-up duration, 
recurrence during that time (yes/no) and if recurred time-to-recurrence.  
- SRS: dose, early and late (≥3 months) toxicity (assessed by CTCAE [Common 
Terminology Criteria for Adverse Events] v5.0), duration of follow-up post-
radiation and tumour response during that time (progression, regression or 
stable disease).  
- FSRT: number of fractions, fractionated dose, total dose, early and late toxicity, 
duration of follow-up post-radiation and tumour response during that time 
(progression, regression or stable disease).     
• Hospital discharge. Data source: medical records. Time-to-discharge was recorded. Data 
sources were also checked for any readmissions/rescans thought to be attributed to the 
incidental meningioma within the study time-frame. Outcome following 
readmissions/rescans was noted.    
• Overall outcomes by the end of the study period (hospital discharge/lost to follow-
up/dead/under follow-up) and follow-up durations. Data source: medical records.  
• Mortality. Any deaths encountered during follow-up were noted. The medical records 
for patients discharged were also examined for mortality data. Duration between 
diagnosis and death were noted for deceased patients. Data source: medical records, 
NHS Spine and CRIS.  
Data collection took place between 04/01/2018 and 21/03/2018. 
3.3.5. Quantitative analysis  
Statistical analyses were performed using SPSS version 24.0 (IBM, Armonk, NY, USA) and R 
version 3.5.0.  
3.3.5.1. Baseline descriptive statistics  
Normally distributed continuous variables were expressed as mean (standard deviation (SD)) 
whereas skewed variables were expressed as median (interquartile range (IQR). Statistical 
significance for differences in baseline characteristics were assessed using Chi-square test for 
categorical variables. The Mann-Whitney U test was used for continuous data. Differences 
were considered to be statistically significant at P <0.05. 
3.3.5.2. Active monitoring endpoint definitions  
Disease progression during Active monitoring was initially defined as one of: i) new symptom 
development, ii) venous sinus invasion, iii) peritumoural signal change, iv) meningioma 
volume exceeding 10 cm3. The first criterion denotes clinical progression while the latter 
three are related to loss of treatment options or “window of curability”. Venous sinus 
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invasion precludes from safe maximal resection. Peritumoural signal change and a 
meningioma volume >10 cm3 are contraindications to SRS. Time to progression was defined 
as the time from radiological diagnosis to the first manifestation of these criteria. Disease 
progression, based on this definition, occurred in 32 (7.94%) patients. 
The association between baseline clinical and radiological factors and time to disease 
progression was assessed using Kaplan-Meier survival analysis. Statistical significance was 
assessed using the Log-rank test. Patients that did not experience disease progression during 
active monitoring and remain under continued observation were censored at the last 
recorded follow-up. Patients discharged from outpatient care, dead during follow-up or lost 
to follow-up were censored at the last date of follow-up where there was no evidence of 
clinical or radiological progression. Subsequently, a joint longitudinal and time-to-event 
model was fitted with the aim of assessing the relationship between the initial meningioma 
volume, volume change over time and time to disease progression whilst adjusting for 
baseline covariates with a Log-rank p≤0.10 (Fig.3.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig.3.2. Kaplan-Meier survival analyses of (A) Tumour signal intensity. (B) Calcification. (C) Peritumoural 
signal intensity. (D) Meningioma size. (E) Proximity to neurovascular structures. (F) Location. (G) 
Multiplicity. (H) Sex. (I) Age. A, B, C, D, E, F and H had a Log-rank p≤0.1  
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Joint modelling has been developed to explicitly account for the dependence between the 
longitudinal change of a continuous factor i.e. meningioma volume in this example, and event 
time data (207). Joint models of this type combine a linear mixed-effects model that 
describes the longitudinal trajectory of a continuous factor, with a proportional hazards 
model for the time-to-event. In the former, covariates and random terms (random intercepts 
and random slopes) are selected using a likelihood-ratio test. In the latter model, the fitted 
exposure trajectory is related to the hazard for event through a parametric Cox analysis. 
To determine how longitudinally changing values of tumour volume relate with the hazard 
for disease progression, we modelled its natural logarithm within a linear mixed regression 
framework that includes random intercept and slopes (referred to as the longitudinal sub-
model). Time (in months) was included as a random effect. Sex, tumour signal intensity, 
peritumoural signal intensity, location and proximity to neurovascular structures were 
included as time-constant covariates with their respective baseline values. 
In the survival sub-model, the predicted time-history of meningioma volume (logarithmic 
transformation) from the linear mixed model was related to the hazard for disease 
progression through a time-varying parametric Cox. The final model included sex, tumour 
signal intensity, peritumoural signal intensity, location and proximity to neurovascular 
structures included as time-constant covariates. The model was developed in 200 bootstrap 
samples. The results of the joint model are presented in Table 3.3.   
Table 3.3. Joint model parameter estimates 
Component Parameter Parameter estimate 
(95% CI) 
P 
Longitudinal Intercept 0.14 (-0.04-0.31) 0.103 
 Time 0.006 (0.005-0.007) <0.001 
 Tumour signal intensity 0.60 (0.23-0.94) <0.001 
 Peritumoural signal intensity 1.45 (1.01-1.94) <0.001 
 Proximity to neurovascular structures 0.37 (0.11-0.60) 0.003 
 Location -0.09 (-0.36-0.14) 0.483 
 Sex 0.12 (-0.20-0.39) 0.469 
Survival Tumour signal intensity 2.66 (1.81-3.92) <0.001 
 Peritumoural signal intensity 1.24 (0.16-2.62) 0.041 
 Proximity to neurovascular structures 0.65 (-0.25-1.73) 0.161 
 Location 0.66 (-0.29-1.63) 0.150 
 Sex 0.23 (-0.88-1.32) 0.678 
 Meningioma volume 0.93 (0.57-1.52) <0.001 
 
The definition of significant meningioma growth used in previous studies has shown a great 
deal of variability. Most definitions are based on a certain extent of growth, such as an 
increase in the maximal diameter >2 mm or relative increase by 15% in comparison to the 
preceding volume (9, 186). The time course over which tumour growth occurred was not 
considered. The main statistical result from the joint data analysis is that tumour volume and 
time are strongly associated with the four disease progression categories. Moreover, given 
that tumour growth is likely to precede these endpoints and certain treatment factors such 
as surgical intervention, in response to growth, might have prevented the observation of 
these endpoints, it is reasonable that survival analyses incorporate tumour volume change 
over time (annual rate) as an additional endpoint.  
38 
 
A recent study on outcomes of untreated symptomatic and asymptomatic meningiomas 
defined significant tumour growth as absolute growth rate (AGR) ≥2 cm3/year OR AGR ≥1 
cm3/year + relative growth rate (RGR) ≥30%/year (151). AGR and RGR calculations for 
meningiomas subject to active monitoring in our study are described below. We used a 
classification and regression tree (CART) analysis to assess the degree of success by which 
these definitions can set our cohort apart stratified by disease progression (based on the four 
endpoints). CART analyses are used to develop models that can classify participants into 
dichotomous splits. Fig. 3.3. outlines the CART analysis.  
 
 
 
 
 
 
 
 
 
 
The CART analysis demonstrated a misclassification rate of 4.7% and an improvement score 
of 0.039. These parameters suggest a significant association between the growth 
definitions used and the four categories of disease progression. The Response Assessment 
in Neuro-Oncology (RANO) group is working towards standardisation of progression and 
response assessments (208). In an attempt to standardise the definition of radiological 
progression for untreated meningioma and in light of this significant association, a decision 
was made to use these parameters to denote significant tumour growth.  
Thus, disease progression in our study was defined as one of:  
i. New symptom development. 
ii. Significant meningioma growth (AGR ≥2 cm3/year OR AGR ≥1 cm3/year + RGR 
≥30%/year). 
iii. Venous sinus invasion. 
iv. Peritumoural signal change. 
v. Meningioma volume exceeding 10 cm3.  
Time to disease progression was defined as the time from radiological diagnosis to the first 
manifestation of these categories. Fig. 3.4. summarises the steps undertaken to reach this 
definition.   
Fig.3.3. CART analysis demonstrating the split in the active monitoring cohort stratified by disease 
progression and non-progression  
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3.3.5.3. Quantification of absolute and relative meningioma growth rates 
AGR was defined as the increase in volume (V) per year in cm3 ((
(𝑉2−𝑉1)
𝑡𝑖𝑚𝑒 (𝑚𝑜𝑛𝑡ℎ𝑠)
) ×  12) whereas 
RGR was defined as the percentage increase in volume per year((
(𝑉2−𝑉1)
𝑉1
𝑡𝑖𝑚𝑒 (𝑚𝑜𝑛𝑡ℎ𝑠)
) ×  12 × 100). 
Due the lack of a standardised imaging surveillance protocol in The Walton Centre in terms 
of timing between scans, imaging modality and duration of follow-up, the growth rate for 
each meningioma was determined a using a linear mixed model (LMM) with random 
intercepts and slopes. LMM allows for missing data and does not require regularly spaced 
time points. A random coefficient model assumes that each meningioma has a different 
intercept and slope. The sum of the regression coefficients of random and fixed effects for 
the slope estimated from the linear model best represented the average growth rate for each 
meningioma.  
3.3.5.4. Association between baseline variables and time to disease progression  
Distribution of disease progression time was estimated by Kaplan-Meier analysis and 
stratified for baseline variables. Statistical significance was assessed using the Log-rank test. 
Patients that did not experience disease progression and remain under continued 
observation were censored at the last recorded follow-up. Patients discharged from 
outpatient care, dead during follow-up or lost to follow-up were censored at the last date of 
follow-up where there was no evidence of clinical or radiological progression. Factors 
included in the analysis were tumour size, tumour signal intensity, peritumoural signal 
intensity, calcification status, proximity to neurovascular structures, location, multiplicity, 
age and sex.   
Fig.3.4. Flow chart of statistical analysis steps carried out to reach the final criteria for disease 
progression 
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A Cox proportional hazards regression model was subsequently developed. Skewed 
continuous variables were transformed into their natural logarithms before being inputted 
into the model. Forward and backward stepwise selection procedures were utilised to 
determine the model of best fit with factor inclusion at p ≤0.05 and exclusion at p≥0.1. 
Certain clinical factors were included in the final model despite being statistically 
insignificant. Model assumptions were tested by examination of Schoenfeld residuals 
(proportional hazards). Influential observations were examined using DFBETA panels.  
Bootstrapping was performed to assess the internal validity of the model. It involves creating 
multiple datasets which are drawn from the sample with replacement. In each of these new 
datasets (n=200), the entire modelling process is repeated and 95% confidence intervals 
(95% CI) are generated for the factors’ hazard ratios (HR).  
Model performance was evaluated by determining the calibration and discriminative 
accuracy. Calibration is the agreement between the observed events of disease progression 
in the study cohort and the predicted events by the model for several meningioma groups at 
certain time-points following diagnosis. To evaluate model calibration, the study population 
was divided into 6 subgroups based on the predicted risk of disease progression. For each, 
the mean predicted probability and the mean observed rate of disease progression were 
determined at 2, 5 and 10 years following diagnosis. A calibration plot compares the 
observed and predicted rates of events for each group. A perfect match (x=y) indicates 
accurate calibration.    
Discriminative accuracy is the model’s ability to differentiate between patients who 
experienced disease progression and those who did not. Discrimination was assessed using 
Harrell's concordance (C) statistic and Chambless and Diao’s time-dependent AUC (area 
under the receiver operating characteristic curve (ROC)) (209, 210).  
3.3.5.5. Development of a prognostic index to predict the risk of disease progression during 
active monitoring   
A prognostic index was developed based on the results of the Cox model. This is calculated 
for each patient as the sum of the covariate values included in the final model, weighted by 
the normal logarithmic transformation of the hazard ratios. As an example, an individual with 
2/3 factors present, the prognostic index would be as follows: (1 (yes) × lnHR1) + (1 (yes) × 
lnHR2) + (0 (no) × lnHR3)  
Risk group stratification was carried out by visual assessment of a prognostic index 
histogram. The prognostic index for each patient was plotted along the y-axis whilst the 
frequencies of observed disease progression and non-progression cases were plotted on the 
x-axis. Wherever a noticeable increase in the proportion of observed disease progression 
cases occurred in relation to the frequency of non-progression cases, a cut-off line was 
drawn. This was carried out twice as to best separate the study cohort into 3 distinct risk 
groups: low-risk, medium-risk and high-risk. The probabilities of disease progression by 0.5, 
1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years were then calculated for each of these groups. Kaplan-
Meier analysis were used to assess the differences across risk groups. 
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3.3.5.6. Assessment of the impact of age, comorbidity and performance status on timing to 
hospital discharge and mortality  
The effects of patient age, comorbidity and functional status on the distribution of disease 
progression and intervention times were assessed in a competing risk analysis. Performance 
status was determined using the WHO scale. This scale is utilised by the neurosurgeons in 
the Walton Centre and for documentation of performance status in multi-disciplinary team 
meetings. Patients were split based on PS into two categories: 0-1 and 2-4.  
Age and comorbidity were combined to generate for each patient a measure of biologic age. 
This was done using the age-adjusted Charlson comorbidity index (ACCI). ACCI is among 
scales validated for use in non-specific site oncology patients and has been shown to predict 
postoperative outcomes in meningioma patient (211, 212). Furthermore, a systematic review 
of comorbidity measures in cancer patients showed ACCI to be among the most reliable 
indices. It also has the advantage of being quick to carry out whilst using routinely collected 
clinical and administrative data (213). Therefore, considering the lack of a validated 
comorbidity index in neuro-oncology populations, we decided to use the ACCI. Patients were 
stratified by ACCI into 3 groups: 0-2, 3-5 and >5. An ACCI score of ≤2 corresponds to patients 
who are young (<60 years) with few or no comorbidities. An ACCI score of 3–5 corresponds 
to either an older patient with few comorbidities, or a younger patient with numerous 
comorbidities, and an ACCI score >5 generally denotes older patient with comorbidities (214, 
215). 
Two competing risk analyses were performed. One assessing the cumulative incidence rate 
(CIR) of therapeutic intervention (surgery or radiotherapy) at different time points following 
diagnosis stratified by PS and ACCI groups. The other evaluated the CIR of disease 
progression. The competing event for the former was mortality which was either observed 
during follow-up or after being discharged from outpatient care. Patients that remain under 
follow-up were censored at the last outpatient clinic appointment. Alive patients discharged 
from outpatient care were censored at last time they were seen by a health physician i.e. 
general practitioner.  
For the disease progression analysis, mortality after hospital discharge could not be used as 
a competing event as the time interval between discharge and death could have witnessed 
radiological changes which meet the disease progression definition. Instead, 4 events were 
regarded as competing in nature, discharge from outpatient care (HD), loss to follow-up 
(LTFU), death during follow-up (DDFU) or an intervention before disease progression 
occurred with the first three grouped together. Censoring was only done for patients who 
remain under follow-up at the last clinic appointment.  
To test the equality across CIR groups, a Fine and Gray test was carried out. Plots of CIRs and 
95% CIs were also generated for visual assessment.  
3.3.5.7. Intervention outcomes  
Intervention details and outcomes are narratively described with no statistical analyses 
carried out.  
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3.3.5.8. Data validity  
Inter and intra-observer variabilities of MR and CT parameters were assessed on a random 
sample of 24 patients. Sample size was calculated using the Bland equation 
1.96
√2𝑁(𝑀−1)
=  0.20 
(216). M is the number of measurements: two by the primary observer to assess 
intraobserver reliability and one by the secondary observer to assess interobserver reliability 
(total=3). N is the sample size which has been calculated to be 24, 0.20 is the β-level (1-
power) and 1.96 is the standard normal deviate. 
Weighted Cohen’s Kappa was used to evaluate the inter- and intraobserver variability of 
categorical variables. Continuous variables were assessed using Bland-Altman plots and the 
intraclass correlation coefficient (ICC). ICC was set to one-way random for intraobserver 
variability and two-way mixed for interobserver variability.   
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3.4. Results  
3.4.1. Study population and baseline clinical characteristics  
Fig. 3.5. describes the study population selection process. A total of 474 patients met the 
inclusion criteria; 18.5% (474/2569) of all meningiomas identified and 9.1% (474/5234) of all 
incidental neurological findings. Thirty-three patients were excluded for lack of 
corresponding medical records. Of the remaining 441 patients, 78.9% (n=348) were female. 
Patient demographics and clinical characteristics are summarised in Table 3.4.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3.5. Patient selection process  
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Table 3.4. Patient demographics and clinical characteristics  
Characteristic   N (%) 
Age  Mean (SD) 63.3 (12.6) 
 <50 70 (15.9) 
 50-59 83 (18.8) 
 60-69 146 (33.1) 
 70-79 103 (23.4) 
 ≥80 39 (8.8) 
Gender Female  348 (78.9) 
 Male 93 (21.1) 
ACCI Median (IQR) 4 (3) 
 0-2 103 (23.4) 
 3-5 212 (48.1) 
 >5 126 (28.6) 
PS Median (IQR) 0 (1) 
 0-1 387 (87.8) 
 2-4 54 (12.2) 
History of malignancy  No 377 (85.5) 
 Yes  In-remission Breast 25 (5.7) 
   Melanoma 5 (1.1) 
   Lung 4 (0.9) 
   Colorectal 3 (0.7) 
   Others* 11 (2.5) 
  Active Lymphoma 5 (0.7) 
   Breast 3 (0.7) 
   Lung 3 (0.7) 
   Melanoma  1 (2.0) 
   Others* 4 (0.9) 
Abbreviations: ACCI=Age-adjusted Charlson comorbidity index; PS=performance status 
*other malignancies included leukaemia, prostate, cervical, endometrial, head and neck, urinary and skin cancers.  
 
3.4.2. Baseline imaging characteristics  
The main indication for imaging was headache (25.9%), cerebrovascular disease (13.8%), 
audiovestibular symptoms (12.9%), head trauma (7.9%), cognitive deficits (6.1%), visual 
problems (5.0%), loss of consciousness (4.1%) and miscellaneous (24.3%) including sinusitis, 
trigeminal neuralgia and lethargy. None of these symptoms were attributed to the 
meningioma. At initial presentation, 200 patients (45.4%) were examined by MRI and CT, 186 
(42.2%) by MRI only and CT was the modality of choice in the remaining 55 (12.5%). MRI 
scanners had the following strengths: 3 Tesla (T) (30.3%), 1.5T (61.9%), 1T (1.3%) and 0.35T 
(6.5%). Meningiomas were single in 426 patients and multiple in 15 resulting in an overall 
meningioma population of 459. Venous sinus involvement was noted for 168 meningiomas. 
Sinuses involved were: SSS (n=95), CS (n=35), SS (n=21), TS (n=15) and the confluence of 
sinuses (n=2). Thirty-five meningiomas were in contact with 1 or more critical neurovascular 
structures and these included: OA (n=17), ICA (n=11), basilar artery (n=7), trigeminal nerve 
(n=4), middle cerebral artery (n=2) and the vertebral artery (n=2). Detailed imaging 
characteristics are outlined in Table 3.5.   
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Table 3.5. Imaging characteristics of the 459 incidental meningiomas included  
Characteristic   N (%) 
Count Single 426 (96.6) 
 Multiple 2 13 (2.9) 
  3 1 (0.2) 
  4 1 (0.2) 
Meningioma volume, cm3 Median (IQR) 1.58 (3.39) 
Meningioma location Origin NSB Convexity  183 (39.9) 
  Parafalcine 77 (16.8) 
  Parasagittal  36 (8.2) 
  Tentorial  21 (4.6) 
  Intraventricular  5 (1.1) 
  SB Sphenoid wing 45 (9.8) 
  Post fossa-lateral & posterior 42 (9.2) 
  Anterior midline 34 (7.4) 
  Post fossa-midline  16 (3.5) 
 Relation to brain lobes Frontal 225 (49.0) 
  Parietal  86 (18.7) 
  Temporal 52 (11.3) 
  Occipital  26 (5.7) 
  Cerebellum 51 (11.1) 
  Brain stem 19 (4.1) 
 Side Right 228 (49.7) 
  Left 214 (46.6) 
  Midline 17 (3.7) 
Venous sinus involvement No  291 (63.6) 
 Yes Separate 49 (10.5) 
  In direct contact 98 (21.4) 
  Invading 21 (4.6) 
Neurovascular structures 
contact  
Yes  35 (7.63) 
 No  424 (92.4) 
Calcification status Absent 81 (17.6) 
 Partial 74 (16.1) 
 Diffuse 109 (23.7) 
Tumour signal intensity Hyper 75 (16.3) 
 Iso 210 (45.8) 
 Hypo 119 (25.9) 
Peritumoural signal intensity 0-5% 373 (81.3) 
 6-33% 16 (3.5) 
 34-66% 13 (2.8) 
 67-100% 2 (0.4) 
Other intracranial 
pathologies  
No 310 (70.3) 
 Yes  Cerebral atrophy 44 (10.0) 
  Small vessel ischaemia  39 (8.8) 
  Haematoma 14 (3.2) 
  Vascular malformation 10 (2.3) 
  Periventricular demyelination 6 (1.4) 
  High-grade tumour 9 (2.0) 
  Low-grade tumour 2 (0.5) 
  Cerebral metastases 2 (0.5) 
  Others 5 (1.1) 
Abbreviations: NSB=non-skull base; SB= skull base 
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3.4.3. Clinical outcomes  
At initial presentation, six patients (1.4%) underwent surgical resection, 50 (11.3%) were 
discharged whilst the remaining 385 (87.3%) entered active monitoring. Of those 385, 38 
eventually required or requested an intervention after a median follow-up period of 24 
months (IQR=33.8); surgery (n=32), surgery + SRS (n=1), surgery + FSRT (n=1), SRS (n=2) and 
FSRT (n=2). Overall outcomes by the end of the study period were: 219 discharged, 12 lost to 
follow-up, 5 dead during follow-up (unrelated to their meningiomas) and 205 under 
continued observation. Fifty-two patients died after a median of 18.5 months (IQR=26) of 
termination of follow-up. Nine had further MRI for unrelated symptoms after a median of 37 
months (IQR=36) and one was patient was readmitted for radiological surveillance. 
3.4.4. Influence of baseline clinical characteristics on the initial management decision 
The differences in clinical characteristics among the three treatment groups are outlined in 
Table 3.6. The responsible physicians were neurosurgeons (n=392) and neurologists (n=48). 
One case was managed by a clinical oncologist. Thirty of 50 discharged patients were under 
the care of a neurologist (p<0.001).   
 
3.4.5. Influence of baseline radiological characteristics on the initial management decision 
The differences in radiological characteristics among the 3 management groups are outlined 
in Table 3.7. Calcification status on CT was available for 255 patients (264 meningiomas), of 
which 246 had a solitary meningioma. One hundred and nine (41.3%) were diffusely calcified, 
74 (28.0%) were partially calcified and the remaining 81 (30.7%) had no evidence of 
calcification. Of the 109 diffusely calcified meningiomas, 25.7% were discharged as opposed 
to 5.16% of patients harbouring partially calcified or non-calcified meningiomas (p<0.001). 
The rates of surgical intervention were 0.9% and 2.58% respectively. Patients discharged 
were also more likely to have no venous sinus involvement (p=0.043). Median meningioma 
Table 3.6. Differences in clinical characteristics between patients in the 3 management groups 
Characteristic  Active monitoring Discharged Surgery P 
Age, N (%) Mean (SD) 62.6 (12.0) 68.5 (15.9) 63.8 (10.5) 0.008 
 <50 62 (88.6) 7 (10.0) 1 (1.4) 0.003 
 50-59 77 (92.8) 5 (6.0) 1 (1.2)  
 60-69 130 (89.0) 13 (8.9) 3 (2.1)  
 70-79 90 (87.4) 12 (11.7) 1 (1.0)  
 ≥80 26 (66.7) 13 (33.3) 0  
Gender, N (%) Female  301 (86.5) 41 (11.8) 6 (1.7) 0.365 
 Male 84 (90.3) 9 (9.7) 0  
ACCI, N (%) Median (IQR) 4 (3) 6 (4) 3.5 (3) <0.001 
 0-2 94 (91.3) 9 (8.7) 0 0.002 
 3-5 193 (91.0) 15 (7.1) 4 (1.9)  
 >5 98 (77.8) 26 (20.6) 2 (1.6)  
PS, N (%) Median IQR) 0 (1) 1 (2) 0 (1) <0.001 
 0-1 346 (89.4) 35 (9.0) 6 (1.6) 0.001 
 2-4 39 (72.7) 15 (27.8) 0  
Malignancy, N 
(%) 
No 330 (87.5) 45 (11.9) 2 (0.5) 0.001 
 Yes 55 (85.9) 5 (7.8) 4 (6.3)  
Abbreviations: CCI=Age-adjusted Charlson comorbidity index; PS=performance status 
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volume in patients discharged was 0.65 cm3 as opposed to 1.70 cm3 in patients subjected to 
active monitoring, and 10.6 cm3 in operated meningioma patients (p<0.001).  
Table 3.7. Differences in imaging characteristics between patients in the 3 management groups 
Meningioma 
characteristic  
 Active 
monitoring 
Discharged Surgery P 
Count, N (%) Single 370 (86.9) 50 (11.7) 6 (1.4) 0.323 
 Multiple 15 (100) 0 0  
Volume, cm3 Median (IQR) 1.70 (3.53) 0.65 (1.10) 10.6 (23.0) <0.001 
Location, N (%) Origin NSB 279 (86.6) 38 (11.8) 5 (1.6) 0.478 
  SB 124 (90.5) 12 (8.8) 1 (0.7)  
Venous sinus 
involvement,  
N (%) 
No  246 (84.5) 42 (14.4) 3 (1.0) 0.043 
 Yes Separate 45 (91.8) 3 (6.1) 1 (2.0)  
 
 
Direct 
contact 
92 (93.9) 5 (5.1) 1 (1.0)  
  Invading 20 (95.2) 0 1 (4.8)  
Neurovascular 
structures 
contact, N (%) 
Yes  33 (94.3) 2 (5.7) 0 0.447 
 No  370 (87.3) 48 (11.3) 6 (1.4)  
Calcification,  
N (%)  
Absent 75 (92.6) 4 (4.9) 2 (2.5) <0.001 
 Partial 68 (91.9) 4 (5.4) 2 (2.7)  
 Diffuse 80 (73.4) 28 (25.7) 1 (0.9)  
Tumour signal 
intensity, N (%) 
Hyper 72 (96.0) 2 (2.7) 1 (1.3) 0.052 
 Iso 197 (93.8) 9 (4.3) 4 (1.9)  
 Hypo 104 (87.4) 14 (11.8) 1 (0.8)  
Peritumoural 
signal intensity, 
N (%) 
0-5% 345 (92.5) 25 (6.7) 3 (0.9) <0.001 
 6-33% 16 (100) 0 0  
 34-66% 11 (84.6) 0 2 (15.4)  
 67-100% 1 (50.0) 0 1 (50.0)  
Abbreviations: NSB=non-skull base; SB= skull base 
 
3.4.6. Active monitoring regimens  
The total number of scans performed following diagnosis was 1303 with an average of 3.4 
(1303/385) scans per patient. Median duration of follow-up was 36.0 months (IQR=41.0). Fig. 
3.6. depicts the active monitoring regimens detailing the number of scans and intervals 
between them. Approximately 90% of scans were performed using MRI (n=1166) whilst the 
remaining were done in a CT scanner. On three occasions, patients were scanned using both 
modalities. Most MRI scans were carried out in 0.35T scanners (n=669, 57.2%). Other MRI 
field strengths included 3T (n=393, 33.6%), 1.5T (n=106, 9.1%) and 1T (n=1, 0.1%). Most 
patients (n=360, 93.5%) were consistently monitored using the same imaging modality: MRI 
in 317 patients and CT in 43. The remaining 25 patients were followed-up alternately with CT 
and MRI studies.  
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1st 2nd 3rd 4th 5th 6th 7th 8th 9th 10th
Number of scans 385 329 246 156 93 51 30 8 4 1
Minimum interval (mos.) 1 3 3 3 3 3 3 5 6 12
Maximum interval (mos.) 24 24 48 36 48 36 36 36 12 12
Median interval (mos.) 6 12 12 12 12 12 12 9 12 12
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3.4.7. Disease progression and subsequent intervention  
During follow-up, 44 (10.9%) meningiomas experienced disease progression. Endpoints 
included: significant tumour growth (n=29, 7.20%), new symptom development (n=12, 
2.98%), increase in peritumoural signal change (n=10, 2.48%), meningioma volume exceeding 
10 cm3 (9/369 with an initial volume <10 cm3, 2.44%) and venous sinus invasion (5/137 
meningiomas adjacent to but not invading a sinus, 3.65%). Symptoms were: seizure (n=6), 
motor deficit (n=3), visual deficit (n=2) and ataxia (n=1). Twenty-eight (6.95%) experienced 
one disease progression endpoint whereas 16 (4.71%) had multiple causes occurring 
concurrently (12 patients, n=2; 3 patients, n=3; 1 patient, n=4). Median time to disease 
progression was 33.0 months (IQR=32.0). The 5- and 10-year active monitoring non-
progression rates were 83.0% (95% CI=77.1-88.9%) and 70.0% (95% CI=56.3-83.7%) 
respectively. Differences in growth patterns, clinical outcomes and the cumulative non-
progression rate plot are demonstrated in Fig. 3.7.   
The longitudinal profiles for meningioma volume against reverse time demonstrate the 
nature of volume progression. Whilst those that did not progress remained static in size 
during follow-up, meningiomas that did, exponentially grew prior to reaching an active 
monitoring endpoint. The time-course over which disease progression occurred is denoted 
by the black dotted intersection line in Fig. 3.7. It shows that if two equally sized meningiomas 
were picked up at the same point in time, the meningioma with growth potential will have 
reached its disease progression endpoint by the 75th month (~6th year) following diagnosis.  
Mean AGR and RGR were significantly higher in the disease progression group (p<0.001). 
Rates of intervention and its prerequisite recommendation were significantly lower in the 
non-progression group (p<0.001), which comprised six patients that requested surgery after 
a median follow-up period of 4.5 months (IQR=12.0). As for the disease progression group, 
an intervention was recommended in 84.1% (37/44) but only carried out in 20 (45.5%) 
patients. Median time to intervention in the two cohorts was 24.0 months (IQR=33.8).  
Fig. 3.6. Active 
monitoring 
regimens in 385 
patients   
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Patients’ primary reason for refusal of treatment was clinical stability as treatment was 
indicated due to radiological changes (disease progression group, n=11; non-progression 
group, n=4). Six patients’ disease progression additionally involved the development of new 
symptoms, which patients either elected to control with antiepileptics (seizure, n=5) or were 
happy to live with due to their minimal effect (visual deficit, n=1). Of 12 patients who 
progressed and had further radiological surveillance available after doing so, 11 (91.7%) 
continued to show evidence of significant tumour growth (median follow-up period after 
initial disease progression=21.0 months (IQR=11.0)). Three epilepsy patients with available 
follow-up had optimal seizure control at their last recorded appointment, despite continued 
meningioma growth for two of them (median follow-up period after initial disease 
progression=18.0 months (IQR=6.)). The antiepileptic used was levetiracetam. The dose was 
not recorded.   
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.7. (A) Profile plot for meningioma volume against reverse time stratified by disease progression (red) and non-
progression (blue) (the origin of the time axis is the disease progression or censoring time; the bold curves are locally fitted 
estimated scatterplot smoothing (LOESS) curves. (B) Table showing the differences in AGR, RGR and clinical outcomes 
between the progression and non-progression groups. (C) Cumulative incidence of non-progression after 10 years of 
diagnosis. Solid blue line demonstrates the absolute cumulative rate while the shadowing around it is for the 95% CIs. 
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3.4.8. Clinical and radiological factors related to disease progression  
Univariate Kaplan analysis (Fig. 3.8), revealed five factors to be significantly associated with 
disease progression: male sex (P=0.005), increasing tumour size (p<0.001), absence of 
calcification (p<0.001), peritumoural signal change (P<0.001) and T2/FLAIR Hyperintense 
meningioma (p<0.001).  
The results of the backward stepwise regression, investigating the set of variables with a 
significance level of p≤0·10, are presented in Table 3.8 (model 1). Two important prognostic 
factors were identified: T2/FLAIR hyperintense meningioma, and meningioma volume 
(natural logarithm). Absence of calcification was not included in the model as hypointensity 
on T2/FLAIR acts a surrogate for calcification on CT (bivariate correlation, p<0.001). Forward 
stepwise regression was subsequently performed to examine the prognostic importance of 
the second set of variables (those with a significance level p>0·10), together with interaction 
terms of prognostic factors identified in the first model and variables excluded from the first 
analysis. No additional prognostic factors were identified. Two radiological parameters were 
however deemed clinically important and were therefore forced into the model: proximity 
to neurovascular structures and peritumoural signal change (model 2).  
 
 
 
 
 
 
The proportional hazards (PH) assumption of model 2 was checked using statistical tests and 
graphical diagnostics based on Schoenfeld residuals which are displayed in Fig. 3.9. The 
statistical tests were not significant for each of the covariates, and the global test was also 
statistically insignificant. All four plots showed a random pattern against time. Therefore, the 
proportional hazards assumption was not violated by model 2.   
To test influential observations and outliers, DFBETA values were visualised (Fig. 3.10). The 
DFBETA is a parameter that measures how much impact each observation has on a particular 
predictor. DFBETA plots showed that none of the observations were terribly influential 
individually, although some of the DFBETA values for “proximity to neurovascular structures” 
and “peritumoural signal intensity” were small compared with the others and large for 
“meningioma volume” and “tumour signal intensity”.  
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Fig. 3.8. Kaplan-Meier survival analyses of (A) Tumour signal intensity. (B) Calcification. (C) Peritumoural signal 
intensity. (D) Meningioma size. (E) Proximity to neurovascular structures. (F) Location. (G) Multiplicity. (H) Sex. 
(I) Age. A, B, C, D, E, F and H had a Log-rank p≤0.1  
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Fig. 3.9. Schoenfeld residual plot for each of the covariates. The solid line is a smoothing spline fit to 
the plot, with the dashed lines representing a ± 2-standard-error band around the fit. None of the 
plots demonstrated a regular pattern with time, and tests were all not statistically significant  
Fig. 3.10. DFBETA plots for each of the covariates. (A) Proximity to neurovascular structures. (B) 
Meningioma volume. (C) Peritumoural signal intensity. (D) Tumour signal intensity. Red circles denote 
potential influential observations. 
 
 
53 
 
3.4.9. A prognostic index to personalise active monitoring strategies 
Based on the results of model 2, a prognostic index was created. For each patient, this could 
be calculated as the sum of the covariate values included in the final model, weighted by the 
normal logarithmic transformation of the hazard ratios. As an example, for an individual with 
a hyperintense meningioma that is 1 cm3 in volume and which is distant from any critical 
neurovascular structures unaccompanied by peritumoural signal change, the prognostic 
index would be: (ln1×ln2.17) + (1×ln10.6) + (0×ln1.58) + (0×ln1·38) = (ln1×0·78) + (1×2.36) + 
(0×.0.46) + (0×0.32) = (0×0·78) + (1×2.36) =  2.36. 
A numeric index based on this formula was then generated for each patient. Aggregates of 
patients’ prognostic indices were subsequently plotted against the observed frequencies of 
progression and non-progression cases in a histogram (Fig. 3.11). Risk group stratification 
was performed by visual assessment and appropriate partitioning by cut-off points allowing 
for the creation of 3 distinct risk groups: low risk (<1), medium risk (<3) and high risk (≥3). 
Group 1 (low risk) comprises patients with a prognostic index of <1·00, group 2 (medium risk) 
includes those with a prognostic index of 1.00–2·99, and group 3 (high risk) are individuals 
with a prognostic index of ≥3·00. Fig. 3.11. shows the disease progression probabilities by 
0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years following diagnosis for each risk group and the Kaplan-
Meier plot of the three groups. Kaplan-Meier analysis demonstrated a significant difference 
between the three groups (Log-rank test, p<0.001).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.11. (A) Histogram of the disease progression and non-progression cases plotted against the prognostic 
index demonstrating the two cut-off lines. (B) Kaplan-Meier plot of non-progression stratified by risk group. (C) 
Table with the non-progressions probabilities at different time points following diagnosis stratified by risk 
group. 
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Fig. 3.12. (A-C) Calibration plots at 2, 5 and 10 years respectively. Predicted values are plotted on the x-axis and observed 
values are plotted on the y-axis. The blue bars represent the 95% CIs. (D) Time-dependent AUC. The solid line represents the 
mean of the AUC while the dashed line represents the median of the AUC. The darker interval in the plot shows the 25% and 
75% quantiles, the lighter interval shows the minimum and maximum. Axes start at 0.80 and end at 1.00 
Discriminative accuracy of the model was assessed by three measures. Harrel’s C statistic 
which was 0.89 (95% CI=0.85-0.93) indicating the prognostic index’s excellent discriminative 
ability, since the confidence interval does not cross zero and the absolute value is very close 
to one. Time-dependent AUC values at 5 and 10 years were 0.87 and 0.84 (0.80≤AUC≤0.90 = 
excellent discrimination). Calibration plots demonstrated overall a good level of agreement 
between the observed and predicted values however some optimism was observed towards 
the lower probabilities at 2 and 5 years and pessimism was noted towards the larger 
probabilities at 10 years (Fig. 3.12).  
 
 
 
 
 
 
 
 
 
 
 
3.4.10. Impact of age-adjusted Charlson comorbidity index and performance status   
The estimated cumulative incidence rate plots of disease progression, and its competing 
risks, grouped by ACCI and PS, are shown In Fig. 3.13. On stratification by ACCI, the rates of 
intervention prior to progression and hospital discharge (HD)/loss to follow-up (LTFU)/death 
during follow-up (DDFU) were statsitcally different acorss the three groups (p=0.009 & 
p<0.001 respectively). The rates of disease progression were not statistically diffferent 
(p=0.09). Differences in incidence rates of disease progression and its competing risk among 
the PS groups were statistically significant (p<0.001). The CIR of each event at differnet time 
points are outlined in Fig. 3.13.  
 
Approximatley 80% of patients with an ACCI ≥6 were discharged, deceased or lost to follow-
up at 5 years following diagnosis, not having encountered disease progression or an 
intervention. Patients with an ACCI 0-2 were 3 time more likely to have experienced disease 
progression at 5 years compared to patients with an ACCI ≥6. No patient with a PS 2-4 had 
disease progression or inteverntion.   
 
The CIR of intervention, with mortality being the sole competing event was also assessed. 
The plots, grouped by ACCI and PS, are shown In Fig. 3.14. On stratification by ACCI, the rates 
of intervention and mortality were statsitcally different acorss the three groups (p<0.001). 
Differences in incidence rates of intervention and mortality in the two PS groups were 
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statistically significant (p<0.001 & p=0.011 respectively). The CIR of each event at differnet 
time points are outlined in Fig. 3.14.  
  
Patients with an ACCI ≥6 were 15-times more likely to die at 5 years of follow-up than to 
receive an intervention. The rates of intervention and mortaility did not differ in patients with 
an ACCI 3-5 and a PS 0-1. Patients with an ACCI 0-2 were at lowest risk of death 5 years from 
diagnosis.  
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3.4.11. Intervention outcomes  
By the end of the study period, 40 patients had surgery (6 at diagnosis and 34 after follow-
up) and 4 patients had primary radiation treatment (2 SRS and 2 FSRT).  
3.4.11.1. Surgical outcomes  
Gross total resection (Simspon I-III) was achieved in 92.5% (37/40) of patients. The three 
subtotal resections (Simpson IV) (7.50%) were for SSS-invading meningiomas, with 2 
residuals deemed to require adjuvant radiation treatment. Neurosurgical complications 
requiring medical therapy or invasive treatment (grades: Ib- IIIb) ocurred in 15.0% (6/40) of 
patients; 2 persisted beyond 30 days postoperatively. These two serious longstanding 
complications arose in patients harbouring SSS-invading meningiomas subject to GTR. Five 
(12.5%) patients experiened grade Ia complications which did not necessitate further medical 
or surgical intervention. Nine (22.5%) patients experienced postoperative medical 
complications, 4 of which (grade Ib) required medical treatment.  The mean age of patients 
with postoperative complications was 55.8 years (SD=10.3). The mean age of patients free of 
complications was 54.1 years (SD=10.5). Median ACCI in the two groups was 2.   
 
Postoperatively all patients were PS 0-1 apart from 3 (7.50%): two patients harbosuring SSS-
invading meningiomas which were subject to GTR (PS 3 & 4) and a patient (PS 3) with a 
posterior fossa meningioma in contact with the tranvserse sinus, which also was subjected 
to GTR.  
 
Surgery revealed WHO grade I meningiomas in 36 patients (90.0%). The remaining 4 were 
atypical WHO Grade II (10.0%). WHO grade I meningiomas were of the following histological 
subtypes: meningiothelial (n=11), psammomatous (n=8), fibrous (n=8), transitional (n=6), 
angiomatous (n=1), microcytic (n=1) and lymphoplasmacyte-rich (n=1).   
 
During a median follow-up period of 35.5 months (IQR=21.8), only 1 (2.50%) meningioma 
recurred. An atypical meningioma had an early recurrence 5 months following GTR (Simpson 
III) which required salvage radiotherapy. The patient was followed-up for 37 months 
following radiation with no evidence of further recurrence before dying due to hospital-
acquired pneumonia unrelated to their meningioma.  
 
3.4.11.2. Radiotherapy outcomes  
Radiotherapy treatment details and outcomes are summarised in Table 3.9.  
Four patients received primary treatment after a duration of active monitoring, 2 received 
adjuvant treatment and 1 patient required salvage radiotherapy for recurrence 5 months 
after surgery. Four patients received FSRT and three had SRS.   
All 7 patients exhibited regression or stable disease during a median follow-up period of 31.0 
months (IQR=25.0).  
Maximum early toxicities were of grade II in 2 (28.6%) patients. Two late grade II toxicities 
were also observed. 
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Fig. 3.15. (A) Bland-Altman plot of mean and difference of meningioma volume for the secondary observer with the 95% 
confidence intervals and the mean shown. All points are within the 95% CI indicating a good level of agreement. (B) Bland-
Altman plot for repeat measurements taken by the original observer, indicating again that there is good agreement. 
3.4.12. Data validity  
Assessment of inter and intraobserver variability across all tested radiological factors 
exhibited a great level of agreement. Volume measurements between the primary and 
secondary raters were consistent (Interobserver, ICC=0.985 (95% CI=0.966-0.999)) and so 
were the repeated measurements recorded by the primary observer (Intraobserver, 
ICC=0.997 (95% CI=0.993-0.999)). Bland-Altman plots were also generated to visualise these 
consistencies (Fig. 3.15). 
   
 
 
 
 
 
 
 
 
 
 
Weighted kappa for agreements between the two raters regarding peritumoural signal 
intensity and venous sinus invasion were between 0.61 and 0.80 indicating a “good” level of 
agreement. Weighted kappa values for the remaining parameters were >0.80 indicating a 
“very good” agreement level.  
Table 3.10. Weighted Kappa values assessing the inter- and intraobserver variability among 
categorical variables 
  Weighted Kappa (95% CI) 
Parameter Inter-observer variability Intra-observer variability 
Calcification 0.82 (0.65-0.99) 0.85 (0.69-1.01) 
Tumour signal intensity  0.80 (0.62-0.98) 0.83 (0.66-1.01) 
Peritumoural signal intensity 0.79 (0.55-1.02) 1.00 (1.00-1.00) 
Venous sinus invasion  0.75 (0.53-0.97) 0.86 (0.67-1.05) 
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3.5. Discussion  
In this study of incidentally-found asymptomatic meningiomas, the prognostic significance of 
several clinical and radiological factors has been tested. Our results indicate that T2/FLAIR 
hyperintensity, increasing meningioma volume, proximity to neurovascular structures and 
peritumoural signal change increase the risk of disease progression within the first 10 years 
following diagnosis. Based on these factors, patients could be stratified into 3 risk groups 
with differing management strategies assigned to each. Patients with an ACCI ≥6 and PS 2-4, 
regardless of risk group allocation, are unlikely to require an intervention for their incidental 
meningiomas during their estimated life-times and thus do not require continued radiological 
surveillance. These clinical and radiological factors have been grouped to create the 
internally-validated prognostic model IMPACT (Incidental Meningioma: Prognostic Analysis 
Using Patient Comorbidity and MR-Tests).  
3.5.1. Radiological factors on standard MR and CT sequences  
Prognostic radiological factors identified in this study as the most important in relation to 
disease progression is lent support by previous published work. Hyperintensity has long been 
recognised as the factor most strongly correlated with progression (180, 185, 202). 
Peritumoural signal change, indicative of vasogenic oedema, and increasing tumour volume 
have also been found to be associated with meningioma growth during follow-up (186, 217). 
Despite the importance of identification of prognostic factors, a vital aspect that’s been 
heavily neglected in previous literature is the timing of such progression during monitoring, 
which plays a major role in defining the necessary length of radiological and clinical 
surveillance for incidental meningiomas. Our results indicate that most patients with 
meningiomas at risk of disease progression will experience progression-related events within 
the 1st 5 years following diagnosis.  
Although statistically insignificant in multivariate analysis, proximity to critical neurovascular 
structures was the last factor added to IMPACT. The reason being is that we aimed to create 
a pragmatic model which recognises that meningiomas in eloquent/skull base locations (i.e. 
medial sphenoid wing compressing the optic chiasm), are at a higher risk of causing 
significant morbidity compared to convexity meningiomas, which of note constitute the 
majority of those discovered incidentally.  The three MR factors: tumour signal intensity, size 
and oedema are not always the primary factors in consideration for decision making; tumour 
location is also a detrimental factor driving recommendations for early intervention (151).  
Although we do not concur with this concept, particularly for small hypo/isointense 
meningiomas with no evidence of peritumoural signal change, as surgery or SRS still carries 
significant risk, we do understand the need to keep a closer eye on these meningiomas and 
so we have accounted for that in the model. 
Calcification status on non-contrast CT was highly correlated with tumour signal intensity on 
T2/FLAIR. Due to this, it was not included in the model, although having proven to be 
significantly associated with non-progression during active monitoring. This is supported by 
the findings of previous papers which note an association between calcification and non-
progression (177, 182). Thus, additional characterisation of growth potential using CT Is not 
warranted for meningiomas identified on MR sequences, given they include T2, FLAIR or 
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susceptibility weighted sequencing (SWI) which has been shown to reliably delineate 
meningioma related calcification (218).  
3.5.2. Age, comorbidity and performance status  
Those three clinical factors are as important as MR characterisation in regard to decision 
making. An intervention succeeding a duration of follow-up in patients with an ACCI ≥6 was 
not carried out, although a minority of patients did in fact experience disease progression. 
Reasons being: i) the high rate of mortality prior to progressing; patients were 15-times more 
likely to die than to receive an intervention at 5 years following diagnosis and this ratio went 
up to 24:1 at 10 years. ii) The threshold for intervention being much higher. Older patients 
with comorbidities should not be subject to surgery or radiation solely due to radiological 
changes as the risk of morbidity and mortality outweighs treatment (211, 212). For these 
reasons we recommend that patient with an ACCI ≥6 are either discharged from outpatient 
care with reassurance that their meningiomas are unlikely to cause them problems during 
their estimated life-times or that clinical monitoring is initiated. A PS 2-4 draws similar 
recommendations. For those patients, the mortality rates at 5- and 10-years following 
diagnosis were much higher and operative or radiation interventions ensue significant 
morbidity and mortality (219, 220).  
3.5.3. Managements strategies based on IMPACT 
Our proposed management strategy for incidental meningiomas is demonstrated in Fig. 3.16. 
Based on the prognostic radiological and clinical factors, incidental meningioma patients 
could be split into 5 groups. Low and medium risk patients with an ACCI ≥6 or PS 2-4 can be 
discharged from outpatient care with no subsequent clinical or radiological monitoring. 
These patients can be counselled about the symptoms that might arise as a result of their 
meningiomas and which might warrant further clinical and radiological examination. Patients 
that fall under the remaining 4 categories are to be followed-up. High-risk patients with an 
ACCI ≥6 or PS 2-4 should be followed clinically with MR or CT scanning offered on clinical 
progression. Low, medium and high-risk patients with an ACCI <6 and a PS 0-1 are to be 
followed clinically and radiologically but at different time points corresponding with the rates 
of disease progression shown in Fig. 3.11. At each appointment, growth rates in concordance 
with disease progression (AGR ≥2 cm3/year OR AGR ≥1 cm3/year + RGR ≥30%/year), 
peritumoural signal intensity, the relationship with neighbouring neurovascular structures, 
and the potential to miss out on the opportunity of SRS, should be examined. Based on any 
observed changes, a recommendation for treatment or a decision to continue follow-up can 
be made. Worked examples in support of these recommendation can be found in Fig. 3.17.  
3.5.4. What to do beyond 10 years?  
Prognosis beyond 10 years of follow-up for incidental meningioma remains unclear. One 
study reported late growth beyond 10 years, however, growth was defined in a time-
independent manner of >2 mm progression in any unidimensional diameter (9). The results 
of the joint model used to define disease progression in this study indicate that the rate of 
tumour growth is of greater clinical significance and so those results based on extent of 
growth definitions are unreliable. Assessment of ACCI and PS at this point in time post 
diagnosis is important. Older patients with comorbidities who remain radiologically and 
clinically stable can be discharged from outpatient care. Patients with a longer life expectancy 
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Fig. 3.16. Proposed clinical guidelines for the management of incidentally-found 
asymptomatic meningiomas. Time intervals in green-shading are our proposed 
time-points of follow-up.  
on the other hand pose a dilemma. Based on the observation that radiological changes 
indicating an intervention are likely to occur early on during follow-up, long-term radiological 
monitoring might not be necessary and instead infrequent clinical monitoring could be 
adopted (i.e. 5-yearly).  
3.5.5. Use of IMPACT in clinical practice 
Although externally invalidated, IMPACT could still be utilised in clinical practice. The number 
of patients included in this study, despite being based on availability rather than a power 
calculation, is large and inclusive of a variety of meningioma volumes and locations. 
Moreover, the demographics of patients included represent the general meningioma 
population making the model more reliable to predict outcomes. The patient cohort was 
derived from a large tertiary centre serving a catchment area of 3.5 million people. The 
parameters associated with internal validation demonstrated adequate accuracy. These 
elements give us confidence in the clinical utility of the model. Fig 3.18. shows how this model 
could be used in clinical practice in the form of an online risk calculator. ACCI calculators in 
different formats are readily available online.  
3.5.6. When should IMPACT not be used? 
Radiation-induced and NF2 associated meningiomas were excluded from this study and 
therefore this model could not be applied to those asymptomatic.  
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Fig. 3.18. A demonstration of how an online risk calculator based on IMPACT will look like 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.5.7. Which intervention to offer on encountering disease progression 
Most patients in this study who progressed went on to undergo surgical resection whilst a 
minority were subject to radiotherapy. Incidental meningiomas are mostly below 10 cm3 
when need to be treated, and so can be managed using either modality, considering the 
adequate control rates following both. Ultimately, the decision will be based on the 
availability of treatment facilities, physician experience, meningioma location and most 
importantly patient preference. Regardless, patients should be counselled about the rates of 
post-intervention morbidity accordingly. It seems clear though that for those meningiomas 
invading a sinus, radical resection should be avoided and instead a combination of STR and 
adjuvant radiotherapy or active monitoring can be used. The burden of morbidity if subject 
to GTR or additional treatment if STR underlines the importance of including venous sinus 
invasion as a radiological criterion of disease progression.  
3.5.8. Histopathological findings  
The majority of operated meningiomas demonstrated WHO grade I histology. This confirms 
the safety of active monitoring as an overall strategy for the managament of incidental 
meningiomas. It also highlights that an early 3-month scan to rule out metastatic disease is 
unneccesary. A recent study on the utility of DNA methylation for classification of 
meningiomas demonstrated that certain meningiomas, although benign grade I according to 
the WHO classficiation, exhibit DNA methylation patterns similar to WHO grade II and III 
meningiomas (221, 222). It would be interesting to test this in our operated cohort which 
demonstrated disease progression prior to surgery.  
Step 1
Step 2
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3.5.9. Study limitations and strengths 
This study is based on a single-centre retrospective cohort with varying follow-up times. 
Nevertheless, as aforementioned, the methodology in this study, the number of patients 
included, and the predictive accuracy parameters give us confidence in the model’s 
performance. Quality of life assessment could not be performed based on clinical notes 
available. However, the fact that the majority of patients were happy to remain under follow-
up indicates that most patients with an incidental meningioma lead normal lives, which is 
supported by the available QoL studies (193, 195). An area that persists to be unexplored is 
the effect of surgery or radiotherapy on QoL and NCF in incidental meningioma patients. 
Although not included in the model, patient anxiety is an important factor that merits 
consideration (223). Evidently, a minority of patients requested surgery and did so after a 
very short duration of follow-up. These patients’ anxiety might or might not be reduced by 
the less frequent monitoring and this needs to be further researched.  
3.6. Conclusions  
IMPACT offers a personalised active monitoring approach with the potential to reduce the 
cost burden of incidental meningiomas. Radiological factors included in the model are 
meningioma volume, tumour signal intensity, peritumoural signal change and proximity to 
critical neurovascular structures. Based on these factors patients could be split into low, 
medium and high-risk groups with rates of disease progression at 5-years being 3%, 28% and 
75% respectively. Further stratification could be performed using patient’s age, comorbidity 
and performance status. External validation of the model should follow but within a multi-
centre prospective study where duration of follow-up is uniform and long. Early intervention 
vs. active monitoring for high-risk meningiomas should be the subject of cost-utility analysis 
to better determine the optimal management strategy within health systems such as the 
NHS.      
 
  
66 
 
  
 
 
67 
 
Chapter 4: Final remarks and future research 
Incidental discovery of meningioma accounts for about 30% of meningiomas diagnosed and 
10% of incidental findings in research and clinical settings. Their management poses a great 
clinical and economic problem. EANO and NCCN suggest active monitoring for their 
management. However, details surrounding the duration of monitoring and the time interval 
between scans lack. The results of the systematic review suggest that clinical or radiological 
progression occurs primarily within the first 5 years following diagnosis indicating that 
rigorous follow-up beyond this timepoint might be unnecessary. Risk factors for clinical 
failure were increasing tumour size and peritumoural signal change. Intervention rates were 
also higher among hyperintense meningiomas suggesting their propensity to demonstrate 
growth during follow-up. The results of the IMPACT study come in support of our findings in 
the systematic review. The risk of disease progression was at its highest during the first 5 
years of follow-up and risk factors included in the generated prognostic model were 
increasing tumour volume, peritumoural signal change and lesion hyperintensity. 
Stratification of patients was performed based on the model and clinical guidelines for active 
monitoring were accordingly designed informing the duration of follow-up and time in 
between scans/appointments. Personalised surveillance has the potential to reduce the cost 
burden of incidental meningiomas and patient anxiety. 
Several aspects to incidental meningiomas warrant further research. All studies performed 
up to this point are retrospective in nature and of short follow-up duration. High-quality 
prospective multi-centre studies are needed. These can take one of two forms: i) a one armed 
study which follows incidental meningioma patients for up to 10-15 years, performing clinical 
and radiological assessments annually. ii) a two-armed study where patients either get 
followed-up according to their risk of progression as worked out per our model, systematic 
review and by consensus or have annual follow-up. The aim of the first study design would 
be to confirm the prognostic factors identified and risk group stratification and to inform 
practice accordingly. The 2nd study type would achieve similar outcomes whilst also 
demonstrating the safety of individualised monitoring and its potential to reduce the costs 
to health care. A similar approach has been adopted in investigating the utility of 
individualised screening for diabetic retinopathy with promising preliminary results (224). 
Needless to say that a trial utilising either design would benefit from a cost-utility analysis, 
quality of life assessment and serum testing which could be subject to spectroscopy-based 
identification of molecular biomarker profiles specific to growing and non-growing 
meningiomas. 
For patients at high risk of disease progression, its not clear whether active monitoring 
supersedes early intervention. A cost-effectiveness study, which we plan to do, will help aid 
decision making for this group of patients.  
The results of the systematic review and the retrospective study suggest that the overall 
majority of operated incidental meningiomas are WHO grade I. The WHO classification is 
admittedly not without its problems. It has been heavily critcised for its subjectivity and 
inadequate delineation of recurrence-prone meningiomas (225). Recent studies 
demonstrated that a fraction of those meningiomas graded as benign do actually in fact 
exhibit methylation profiles similar to the more aggressive WHO grade II and III meningiomas 
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and so it’s worth testing whether those that do fail active monitoring by demonstrating rapid 
growth fit those methylation patterns (221, 222).  
In conclusion, this thesis has achieved it primary aims of generating a prognostic index 
informing guidelines for the management of incidental meningiomas. It also underlines 
several aspects to incidental meningiomas which warrant further research.  
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Appendix 4. ICOM classification of meningioma location 
 
Main category Subcategories   
Convexity Anterior 1 Posterior1  
Parasagittal Anterior1 Posterior1 Falco-tentorial 
Parafalcine Anterior1 Posterior1 Falco-tentorial 
Sphenoid wing Lateral Medial (including ACP)  
Anterior midline Cribriform plate or 
olfactory groove2 
Planum Tuberculum and 
diaphragma sellae 
Post fossa - midline Clival Petro-clival Anterior foramen 
magnum4 
Post fossa – 
Lateral & posterior 
Petrous Squamous occipital Posterior foramen 
magnum4 
Tentorial Supratentorial Infratentorial  
Intraventricular    
Pineal region5    
 
1 The main attachment is located anterior or posterior, respectively, to the coronal suture 
2 Arising between the crista galli and the fronto-sphenoid suture 
3 Arising between the fronto-sphenoid suture and the limbus sphenoidale 
4 The main attachment is located anterior or posterior, respectively, to the hypoglossal 
canal 
5 No obvious tentorial attachment 
 
